YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2019 - 2020

Student's
Name : .....
Number : .....

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

CONTENT **Page**

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

AIM OF MEDICAL EDUCATION PROGRAM

*"Consensus Commission Report" based on draft compiled at "*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*"

AIM

The aim of medical education program ***is to graduate physicians*** who

- **are aware of** the local and global health issues
- **have acquired competence** in knowledge, skills and attitudes to manage and provide primary health care service
- **know**, **apply** and **care** for ethical principles of the medical profession
- **keep up with** current knowledge at national and international level
- **are capable of** systematical thinking
- **are** investigative and questioning
- continually **renovate** and **improve** themselves
- **are capable of** teamwork
- **use** technology competently in medicine and related areas
- **have** effective communication skills
- **have** community leadership qualifications

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

PROGRAM OUTCOMES OF MEDICAL EDUCATION PROGRAM

Abbreviations: PO: Program Outcomes, POD: Program Outcomes Domain, PODG: Program Outcomes Domain Group

PODG.1. Basic Professional Competencies

POD.1.1. Clinical Competencies

PO.1.1.1. ***values*** preventive health services, ***offers*** primary prevention (i.e. prevention of diseases for the protection of health), secondary prevention (i.e. early diagnosis and treatment) tertiary prevention (i.e. rehabilitation) and quaternary prevention (i.e. prevention of excessive and unnecessary diagnosis and treatment) services, ***provides*** consultancy on these issues.
PO.1.1.2. ***employs*** a patient-centered approach in patient management.
PO.1.1.3. ***recognizes*** most frequently occurring or significant clinical complaints, symptoms, signs, findings and their emergence mechanisms in clinical conditions.
PO.1.1.4. ***takes*** medical history from the applicant himself/herself or from the individual's companions.
PO.1.1.5. ***does*** general and focused physical and mental examination.
PO.1.1.6. ***interprets*** findings in medical history, physical and mental examination.
PO.1.1.7. ***employs*** diagnostic procedures that are used frequently at the primary health care level.
PO.1.1.8. ***selects*** tests that have evidence-based high efficacy at the primary health care level and ***interprets*** results.
PO.1.1.9. ***makes*** clinical decisions using evidence-based systematic data in health care service.
PO.1.1.10. ***performs*** medical interventional procedures that are used frequently at the primary health care level.
PO.1.1.11. ***manages*** healthy individuals and patients in the context of health care services.
PO.1.1.12. ***keeps*** medical records in health care provision and ***uses*** information systems to that aim.

POD.1.2. Competencies related to Communication

PO.1.2.1. throughout his/her career, ***communicates*** effectively with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals, organizations and institutions.
PO.1.2.2. ***collaborates*** as a team member with related organizations and institutions, with other professionals and health care workers, on issues related to health.
PO.1.2.3. ***recognizes*** the protection and privacy policy for health care beneficiaries, co-workers, accompanying persons and visitors.
PO.1.2.4. ***communicates*** with all stakeholders taking into consideration the socio-cultural diversity.

POD.1.3. Competencies Related to Leadership and Management

PO.1.3.1. ***manages*** and ***leads*** within the health care team in primary health care organization.
PO.1.3.2. ***recognizes*** the principles of health management and health sector economy, models of organization and financing of health care services.
PO.1.3.3. ***recognizes*** the resources in the health care service, the principles for cost-effective use.

POD.1.4. Competencies related to Health Advocacy

PO.1.4.1. ***recognizes*** the health status of the individual and the community and the factors affecting the health, ***implements*** the necessary measures to prevent effects of these factors on the health.

PO.1.4.2. ***recognizes*** and ***manages*** the health determinants including conditions that prevent access to health care.

POD.1.5. Competencies related to Research

PO.1.5.1. ***develops***, ***prepares*** and ***presents*** research projects

POD.1.6. Competencies related to Health Education and Counseling

PO.1.6.1. ***provides*** consultancy services and ***organizes*** health education for the community to sustain and promote the health of individual and community**.**

PODG.2. Professional Values and Perspectives

POD.2.1. Competencies related to Law and Legal Regulations

PO.2.1.1. ***performs*** medical practices in accordance with the legal framework which regulates the primary health care service.

POD.2.2. Competencies Related to Ethical Aspects of Medicine

PO.2.2.1. ***recognizes*** basic ethical principles completely, and ***distinguishes*** ethical and legal problems.

PO.2.2.2. ***pays importance to*** the rights of patient, patient's relatives and physicians, and ***provides*** services in this context.

POD.2.3. Competencies Related to Social and Behavioral Sciences

PO.2.3.1. ***relates*** historical, anthropological and philosophical evolution of medicine, with the current medical practice.

PO.2.3.2. ***recognizes*** the individual's behavior and attitudes and factors that determine the social dynamics of the community.

POD.2.4. Competencies Related to Social Awareness and Participation

PO.2.4.1. ***leads*** community with sense of responsibility, behavior and attitudes in consideration of individual behaviors and social dynamics of the community, and if there is a necessity, ***develops*** projects directed towards health care services.

POD.2.5. Competencies Related to Professional Attitudes and Behaviors

PO.2.5.1. ***displays*** a patient-centered and holistic (biopsychosocial) approach to patients and their problems.

PO.2.5.2. ***respects*** patients, colleagues and all stakeholders in health care delivery.

PO.2.5.3. ***displays*** the proper behavior in case of disadvantaged groups and situations in the community.

PO.2.5.4. ***takes*** responsibility for the development of patient safety and healthcare quality.

PO.2.5.6. ***evaluates*** own performance as open to criticism, ***realizes*** the qualifications and limitations.

PODG.3. Personal Development and Values

POD.3.1.Competencies Related to Lifelong Learning

PO.3.1.1. ***embraces*** the importance of lifelong self-learning and ***implements***.

PO.3.1.2. ***embraces*** the importance of updating knowledge and skills; ***searches*** current advancements and ***improves*** own knowledge and skills.

PO.3.1.3. ***uses*** English language at least at a level adequate to follow the international literature and to establish communication related to the profession.

POD.3.2. Competencies Related to Career Management

PO.3.2.1. ***recognizes*** and ***investigates*** postgraduate work domains and job opportunities.

PO.3.2.2. ***recognizes*** the application requirements to postgraduate work/job domains, and ***distinguishes*** and ***plans*** any requirement for further training and work experience.

PO.3.2.3. ***prepares*** a resume, and ***recognizes*** job interview methods.

POD.3.3. Competencies Related to Protection and Development of Own Physical and Mental Health

PO.3.3.1. ***implements*** the rules of healthy living.

PO.3.3.2. ***displays*** appropriate behavior specific to work under stressful conditions.

PO.3.3.3. ***uses*** self-motivation factors.

COORDINATION COMMITTEES

(TEACHING YEAR 2019 – 2020)

PHASE-III COORDINATION COMMITTEE

Hale ARIK TAŞYIKAN, MD, Assist. Prof. (Coordinator)
Hasan AYDIN, MD, Prof. (Co-coordinator)
Erdem SÖZTUTAR, MD, Assist. Prof. (Co-coordinator)
Emine Nur ÖZDAMAR, Assist. Prof. (Co-coordinator)
Arzu YALÇIN, Assist. Prof. (Co-coordinator)

ICP-III COORDINATION COMMITTEE

Özlem TANRIÖVER, MD, Prof. (Coordinator)
Ayşe Arzu AKALIN, MD, Assist. Prof. (Co-coordinator)

ELECTIVE COURSES COORDINATION COMMITTEE

Ayşe Arzu AKALIN, MD, Assist. Prof. (Coordinator)
Seda GÜLEÇ, PhD. Assoc. Prof. (Co-coordinator)

DESCRIPTION and CONTENT

Physiopathological process and pathological process.

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepathology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophtalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education.

AIMS and LEARNING OBJECTIVES of PHASE III

AIMS

In evidence based manner:

1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
3.2. ***to convey*** knowledge on epidemiology,
3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,
4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,
8. ***to equip with*** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of body systems.
2.0. ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0. ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0. at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,
• for healthy conditions in an individual or community with a request, or
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
• health care processes,
• acquisition of subjective or objective data, information and knowledge required for clinical decision making,
• clinical decision making process,

• clinical decisions and
• clinical practices
which are required for management at primary health care service level.
7.1. practice of history taking and physical examination (*cardiovascular, pulmonary, gastrointestinal, gynecological, breast, neonatal, prepubertal/pubertal, neurological/neuropsychiatric, musculoskeletal*)
7.2. evaluation of emergency case (*sepsis and septic shock, dyspnea, acute abdominal pain, urological emergencies, neurological emergencies, trauma*)
7.3. approach to healthy individual or patient (*fever, cardiovascular disease, chest pain, cough and hemoptysis, dyspnea, anemia, lymphadenopathy, diarrhea, pregnancy, urinary tract infection, neurological symptoms, headache, depression, dementia, musculoskeletal dysfunction*)
7.4. laboratory and imaging tests/examinations
7.4.1. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests:
i. *(venous blood collection*)
ii. *(thyroid function tests, diabetes tests)*
2. medical microbiology tests:
i. *(urine sample collection, throat swab specimen, sputum sample collection, urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection, wound sample collection, blood collection for culture*)
ii. *(urine strip/dipstick test, urine culture, rapid screening (antigen/antibody) tests, throat culture, sputum culture, urethral-vaginal-cervical discharge culture, fecal culture, wound culture, blood culture)*
3. medical pathology tests:
i. *Pap smear collection*
ii. *Pap smear*
4. other laboratory tests:
i. *(peripheral/venous blood collection for hematology tests, blood sample collection for therapeutic drug monitoring)*
ii. *(pulmonary function tests, hematology tests for anemia, monitarization of drug therapy)*

5. radiological examinations: *(radiological examinations in gynecology, breast imaging, uroradiology, conventional neuroradiological examinations, spinal neuroradiology, cranial CT, cranial MRI, radiological imaging of musculoskeletal system, radiological examinations in benign ve malign tumors of bones)*
6. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases, radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphyi, PET in lung cancer, nuclear medicine tests in hematology, scintigraphy of liver/spleen, PET in gastrointestinal system tumors, radioisotope imaging of thyroid and parathyroid, renal scintigrahy (GFR, ERPF, Renogram), brain perfusion scintigraphy, brain PET, bone scintigraphy)*

7.4.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests: *(diabetes tests, cardiac markers, coagulation tests, blood gases).*
2. medical microbiology tests: *(urine strip/dipstick test, rapid screening (antigen/antibody tests)*
3. other laboratory testsi: *(hematology-peripheral blood smear examination, hematology-complete blood count)*

7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. practicing non-intervention or intervention
7.8. referral/transport of healthy individual or patient

INSTRUCTIONAL DESIGN of PRECLINICAL YEARS

In Phase I, II and III, the formation of committees is based on a thematic structure. This structure corresponds to organizational levels of human body such that macromolecule, organelle, cell, tissue, organ systems and finally introduction to pathogenesis.

- Phase I: Normal structure and function of human body at molecular, cellular, tissue and organ level.
- Phase II: Normal structure and function of human body at system and multi-system level, and introduction to pathogenesis.
- Phase III: Physiopathological and pathological processes in human body.

Besides this thematic structure, there is a continuous clinical skills education in Phase I, II and III, as “Introduction to Clinical Practice -I, -II and -III” courses.

Therefore, the core medical courses are;

- Phase I: MED 104 Basic Medical Sciences I, MED 102 Introduction to Clinical Practice I, MED 103 Anatomical Drawing,
- Phase II: MED 201 Basic Medical Sciences II, MED 202 Introduction to Clinical Practice II,
- Phase III: MED 302 Introduction to Clinical Sciences, MED 303 Introduction to Clinical Practice III.

The learning objectives of the phase include learning objectives of core courses. The learning objectives of committees include learning objectives of core courses’ components for the committee.

INTRODUCTION to CLINICAL SCIENCES (MED 302)

AIMS

In evidence based manner:

1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;

3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
3.2. ***to convey*** knowledge on epidemiology,
3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,

4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of body systems.
2.0. ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0. ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0. at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings

of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request, or
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes,
- acquisition of subjective or objective data, information and knowledge required for clinical decision making,
- clinical decision making process,
- clinical decisions and
- clinical practices

which are required for management at primary health care service level.
7.1. evaluation of emergency case (*sepsis and septic shock, dyspnea, acute abdominal pain, urological emergencies, neurological emergencies, trauma*)
7.2. approach to healthy individual or patient (*fever, cardiovascular disease, chest pain, cough and hemoptysis, dyspnea, anemia, lymphadenopathy, diarrhea, pregnancy, urinary tract infection, neurological symptoms, headache, depression, dementia, musculoskeletal dysfunction*)
7.3. laboratory and imaging tests/examinations
7.3.1. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests:
i. *(venous blood collection*)
ii. *(thyroid function tests, diabetes tests)*
2. medical microbiology tests:
i. *(urine sample collection, throat swab specimen, sputum sample collection, urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection, wound sample collection-,blood collection for culture*)
ii. *(urine strip/dipstick test, urine culture, rapid screening (antigen/antibody) tests, throat culture, sputum culture, urethral-vaginal-cervical discharge culture, fecal culture, wound culture, blood culture)*
3. medical pathology tests:
i. *(Pap smear collection)*
ii. *(Pap smear)*

4. other laboratory tests:
i. *(peripheral/venous blood collection for hematology tests, blood sample collection for therapeutic drug monitoring)*
ii. *(pulmonary function tests, hematology tests for anemia, monitarization of drug therapy)*

7.3.2. imaging tests/examinations based on disciplines/subdisciplines:
1. radiological examinations: *(radiological examinations in gynecology, breast imaging, uroradiology, conventional neuroradiological examinations, spinal neuroradiology, cranial CT, cranial MRI, radiological imaging of musculoskeletal system, radiological examinations in benign ve malign tumors of bones)*
2. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases, radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphyi, PET in lung cancer, nuclear medicine tests in hematology, scintigraphy of liver/spleen, PET in gastrointestinal system tumors, radioisotope imaging of thyroid and parathyroid, renal scintigrahy (GFR, ERPF, Renogram), brain perfusion scintigraphy, brain PET, bone scintigraphy)*

7.3.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests: *(diabetes tests, cardiac markers-, coagulation tests-, blood gases).*
2. medical microbiology tests: *(urine strip/dipstick test, rapid screening (antigen/antibody tests)*
3. other laboratory testsi: *(hematology-peripheral blood smear examination, hematology-complete blood count)*

7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. referral/transport of healthy individual or patient

INTRODUCTION to CLINICAL PRACTICE- I-II-III (MED 102, 202, 303)

AIM of ICP PROGRAM

This course aims to equip the students with basic medical skills such as history taking regarding to systems and in general, physical and mental examination in simulated environments in pre-clinical period and to give the students opportunity to develop skills by applying non –invasive or invasive procedures on the mannequins before encountering with real patients. The students improve the gained skills by observing real encounters in the clinical settings during 2nd and 3rd year.

Description

ICP is a three year longitudinal course that aims to introduce students to the concepts and main elements of medical practice. It will also be an introduction to the medical profession as a whole and will provide a foundation for clinical practice. The course provides knowledge, cognitive and motor skills and experience in fundamental processes and aspects of medical practice. It involves the application of scientific theory, quality assurance and evidence-based best practice protocols.

Credit Facility:

This course has 5 ECTS credits for the first and third year students while it is 4 ECTS for the second year students and all of the students are required to pass this course in order to pass the year.

Content of the ICP I-II-III

First year medical students gain knowledge on First Aid approaches, develop skills in Basic Life Support, Patient/Casualty Transportation and Bandaging Techniques regarding to First Aid. They also acquire basic knowledge on communication and experience patient-doctor encounter with simulated patients (SP's).

The second years ICP Program consist of modules like handwashing, wearing sterile gloves, assessing vital signs, nasogastric intubation, bladder catheterization, intramuscular, subcutaneous, intradermal and intravenous injections as well as iv. catheterization.

In the third year medical students practice with SP's clinical skills like history taking and physical examination focused on body systems and in general and also mental examination. They also gain clinical skills such as suturing techniques and Advanced Cardiac Life Support.

Clinical Skills Laboratory

The Clinical Skills Laboratory is designed for teaching and assessing students at undergraduate level (during the preclinical period from first-year to third year). The lab provides learners with the ideal setting to practice the clinical skills of history taking, physical examination, communication, and gives opportunities to practice invasive and non invasive procedural skills on mannequins.

Each exam room is equipped with video cameras and microphones to record the encounter. An observation area at the center of the lab allows faculty and students to observe the encounters live or view digital recordings for subsequent analysis.

Simulated Patients (SPs)

The simulated patient encounters provide transition of students from the classroom to standardized patient contact in safe environments.

Encounters with specially trained individuals, known as simulated patients (SPs), simulate specific cases in outpatient and emergency settings. The pool of SPs consist of adults, from various backgrounds.

Clinical cases are created through research and extensive training of the patients portraying these roles.

Assessment: The Assessment procedure of ICP is given in Assessment Table in this booklet.

Rules for Attendance of the Students: Students are grouped into 4 and group lists are announced in the announcement board at the beginning of the year. Any changes to practical groups on a week by

week basis, will only be considered in exceptional situations such as a medical one. Any changes must be requested by a petition along with relevant documentation to the course coordinator. Any change in sessions will only be accepted interchangeably with another student in another group based on availability of work spaces and course coordinator's discretion (based on evidence provided).
Students are required to follow the rules of professional ethics in the laboratory at any time.

When an OSCE is conducted both students and faculty members complete a written evaluation of the event for the improvement of the course and OSCE.

INTRODUCTION to CLINICAL PRACTICE III (ICP-III) (MED 303)

AIM

The aim of ICP III Program is to equip Phase III students with basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

KNOWLEDGE

1. define the basic terminology used in general and organ system spesific physical examination.
2. describe the steps of history taking and physical examination (cardiovascular, pulmonary, ear/nose/throat, gastrointestinal, gynecological, obstetric, breast, neonatal, prepubertal / pubertal, neurological / psychiatric, musculoskeletal)**.**
3. describe suture materials and choose the appropriate material**.**

SKILLS

1. **apply** Advance Cardiac Life Support on an adult model in accordance with the skill procedure**.**
2. **perform** sutures in accordance with the skill procedure**.**
3. **perform** history taking and physical examination (cardiovascular, pulmonary, ear/nose/throat, gastrointestinal, gynecological, obstetric, breast, neonatal, prepubertal / pubertal, neurological / psychiatric, musculoskeletal) on simulated patients or mannequins in accordance with the skill procedure.
4. **perform** intramuscular, intradermal and subcutaneous injection as well as intravenous cannulation applications in an adult model in accordance with the skill procedure**.**
5. **describe** the process to be carried out to the patient before any intervention**.**

ATTITUDE

1. **value** the importance of informed consent
2. **pay** attention to patient privacy
3. **value** the importance of not exceeding the limits of his/her own competency level.

SCIENTIFIC RESEARCH and PROJECT COURSE - III

AIM

The aim of Scientific Research and Project Course - III (SRPC – III) is to equip third year medical students with knowledge and skills of writing a scientific project proposal, and furthermore to equip with basic knowledge on scientific career and with skills of preparing CV and cover letter for scientific career.

ASSESSMENT PROCEDURE

For the assessments of the medical students for the SRPC-III, it is calculated out of 100 points; 50% will be graded at the end of the first semester on CV and cover letter preparation assessment and 50% will be graded via scientific project proposal at the end of the second semester.

CV and cover letter assessment should be loaded to Moodle program **before 17 January 2020 Friday at the end of the first semester.** The constraints of the scientific project proposal assignment will be discussed in Small Group Study hours, and during the year small group discussion hours on the program will be used to prepare the proposal. The project proposal should be loaded to Moodle program **before 15 May 2020 Friday.**

Scientific Research and Project Course has 2% contribution to Term Score (TS).

Please note that it is mandatory to attend to SRPC lecture hours in the program. There will be no acceptance of assignments after the prescheduled dates.

ELECTIVE COURSES

Elective courses aim to add complementary educational experiences to the medical school curriculum in order to improve comprehension of biopsychosocial approach of medical students, besides offering an opportunity to extend knowledge of interest in specific domains. For further information on elective course contents, please see: https://med.yeditepe.edu.tr/tr/ders-programi-kitapciklari

The following courses (2 ECTS credits each) will be offered in Spring semester. Each student has to choose one of these elective courses. The selection and enrollment procedure will be announced by the phase coordinator.

Code	Subject		
MED 614	**Personal Trademark Development**		
Goals	The aim of this course is to equip the students with skills in creating personal image for successful business life and with appropriate behavior in social platforms.		
Content	Business Etiquette creation techniques and personal image methodologies with case studies.		
Course Learning Outcomes	At the end of this course, the student should be able to create personal brand for successful business life. use behavioral codes for business etiquette.		
Assessment		**NUMBER**	**PERCENTAGE**
	Midterm Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	25
	Presentations and Reports (Interactive Team Work, Social Skills Development, based on subjects studied during classes and applications of them on MED areas & discussions after each presentation)	1	25
	Attendence (Showing interest to classes, performance during discussion times, performance during pair works, attending classes etc.)		5
	Quiz ((Short quizzes to keep students updated about lectures, prepare them to midterm & final, based on subjects studied in the class, Essay or MCQ)	3	5
	Final Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	40
	Total		**100**

Code	Subject		
MED 615	**Innovation Management**		
Goals	The aim of this course is to convey to the students knowledge on innovative approaches for visionary life, describe the philosophy of futurism.		
Content	Strategies for futurism and applied case studies for personal innovation.		
Course Learning Outcomes	At the end of this course, the student should be able to use futuristic strategies to create innovative approaches. use innovative and creative thinking techniques in professional life.		
Assessment		**NUMBER**	**PERCENTAGE**
	Midterm Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	25
	Presentations and Reports (Interactive Team Work, Social Skills Development, based on subjects studied during classes and applications of them on MED areas & discussions after each presentation)	1	25
	Attendence (Showing interest to classes, performance during discussion times, performance during pair works, attending classes etc.)		5
	Quiz ((Short quizzes to keep students updated about lectures, prepare them to midterm & final, based on subjects studied in the class, Essay or MCQ)	5	5
	Final Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	40
	Total	8	**100**

Code	Subject		
MED 616	**Medical Management and New Services Design Skills**		
Goals	The aim of this course is to develop leadership skills to manage a team and organizational skills in the case of emergency and lack of crew. Moreover, empathy skills will be developed to create better relationship with the patients, coworkers and customers.		
Content	Leadership Styles, Skills needed in Med, Strategies for New Generation Leadership, Empathy Techniques, Problem Solving with Empathy, and Conciliation with Empathy.		
Course Learning Outcomes	At the end of this course, the student should be able to develop leadership skills to manage teams. use empathy techniques for conciliation with their patients and co-workers.		
Assessment		**NUMBER**	**PERCENTAGE**
	Midterm Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	25
	Presentations and Reports (Interactive Team Work, Social Skills Development, based on subjects studied during classes and applications of them on MED areas & discussions after each presentation)	1	25
	Attendence (Showing interest to classes, performance during discussion times, performance during pair works, attending classes etc.)		5
	Quiz ((Short quizzes to keep students updated about lectures, prepare them to midterm & final, based on subjects studied in the class, Essay or MCQ)	4	5
	Final Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	40
	Total		**100**

Code	Subject		
MED 617	**Personal Brand Management Skills**		
Goals	This course aimes to teach how to deal with stress under different conditions. Besides, effective production skills under stress and time constraints will be subject of the course. This course also will be very helpful for career development. The tools will be offered to students for better communication, presentation and managerial skills.		
Content	In the content of this course; stress and time management for effective production, personal goal settings, motivation and effective communication will be used. Breathing techniques, diction exercises and body language will help to improve student's personal development. Moreover, managerial skills development subjects will be held. Presentations and homework will be used as effective learning tools in this course.		
Course Learning Outcomes	At the end of this course, the student should be able to apply stress and time management skills in their personal development and career.		
Assessment		**NUMBER**	**PERCENTAGE**
	Midterm Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	25
	Presentations and Reports (Interactive Team Work, Social Skills Development, based on subjects studied during classes and applications of them on MED areas & discussions after each presentation)	1	25
	Attendence (Showing interest to classes, performance during discussion times, performance during pair works, attending classes etc.)		5
	Quiz ((Short quizzes to keep students updated about lectures, prepare them to midterm & final, based on subjects studied in the class, Essay or MCQ)	4	5
	Final Exam (MCQ, Fill in the Blanks, T/F Questions, mostly based on case studies)	1	40
	Total		**100**

Code	Subject		
MED 621	**Epidemiological Research and Evidence Based Medicine**		
Goals	The aim is to provide understanding of epidemiological language and terminology by reading, examining and discussing various types of epidemiological research papers and to develop the desire and enthusiasm for epidemiological studies.		
Content	Different sessions for each type of epidemiological research will be held. The selected research types are case report, cross-sectional, case- control, cohort study, and randomized controlled trial.		
Course Learning Outcomes	At the end of this course, the student should be able to comprehend various types of epidemiological research. explain basic epidemiological terminology.		
Assessment		**NUMBER**	**PERCENTAGE**
	Group work performance		50
	Presentations		50
	Total		**100**

Code	Subject		
MED 622	**Application of Economics in Health Care**		
Goals	This course aims to teach the essentials of economics and its' core concepts' relevance with health-care.		
Content	Tools and concepts of traditional Microeconomics Theory, health production function, cost & benefit analysis, demand for health insurance and health care markets.		
Course Learning Outcomes	At the end of this course, the student should be able to • explain the applications of micro-economic theories in health related areas. • discuss the causes of market failure. • list the factors effecting the demand for health. • explain health insurance supply and demand. • analyse how health care market operates.		
Assessment		**NUMBER**	**PERCENTAGE**
	Mid-terms	1	80
	Quizzes, Homeworks	5	5
	Attendance	14	15
		Total	100
	Contribution of Final Examination to Overall Grade		45
	Contribution of In-Term Studies to Overall Grade		55
		Total	100

Code	Subject
MED 624	**Narrative Medicine**
Goals	This course aims to build close reading skills and to develop approaches to reflective writing in the clinical setting. To equip with a capacity to read deeply, extensively, and rigorously the clinical setting and conditions of the cases so as to recognize the writer/artist and (here, the dividend) the reader/ the viewer opinions comparatively.
Content	The care of the sick unfolds in stories. The effective practice of healthcare requires the ability to recognize, absorb, interpret, and act on the stories and plights of others. Medicine practiced with narrative competence is a model for humane and effective medical practice. It addresses the need for patients and caregivers to voice their experience, to be heard and to be valued, and it acknowledges the power of narrative to change the way care is given and received. Narrative Medicine empowers the overarching goals of medicine, public health, and social justice, as well as the intimate, interpersonal experiences of the clinical encounter. There is a seminar part of the course, and the workshop will be an interactive session. The instructor helps students to discuss art pieces with some questions. At the end of the session, a project is given to write a reflective piece in a limited time. The writings could be shared depending on the writers' will and feedbacks are provided as a class by using close reading techniques. Artworks (literary works such as poetry, story, novels, visual artworks such as paintings, photographs, movies, comic books, or music) will be shared by the instructor.
Course Learning Outcomes	At the end of this course, the student should be able to • improve their close reading skills for medical narratives in the clinical setting. • recognize their emotions and learn emotional honesty by learning and experiencing a reflective writing approach • learn to understand/ listen/recognize more closely the artistic narratives and the clinical narratives as well. • develop a humanistic attitude such as compassion, tolerance for diversity and social justice in the clinic setting. • understand how important the creativity is to a clinician. • understand how the humanities and humanistic values influence and protect the clinician in the clinical setting. • recognize, understand and express their own feelings. • gain skills in telling, listening and understanding the illness experiences. • learn to increase the communication skills between the patient-physician and learn empathy in the clinical setting • gain new skills for a humanistic and effective healthcare service • understand the importance of writing for a clinician for understanding the self and expressing the self.

Assessment		**NUMBER**	**PERCENTAGE**
	Midterm		
	Assignments/weekly feedbacks	1	50
	Final Examination	1	50
		Total	100
	Contribution of Final Examination to Overall Grade	1	50
	Contribution of In-Term Studies to Overall Grade	1	50
		Total	100

Code	Subject
MED 627	**Presentation of Medicine on Media**
Goals	This course aims to teach deep understanding to approaches & visual methods/tools available as community communication media in conveying medical knowledge. To analyze technical features and to develop an understanding of aesthetics behind. To develop skills in conveying messages presented via media tools.
Content	Sensual and perceptual theories of visual communication. Analysis and reading the meaning of the images presented in the media as a PR tool.
Course Learning Outcomes	At the end of this course, the student should be able to • recognize the meaning of the visual literacy as intellectual property • describe the physical features of the light and theory of vision • analyze the images with the help of sensual and perceptual theories such as Gestalt, Constructivism, Semiology and Cognitive Approach. • recognize the differences between advertising, journalism and public relations. • describe the historical and cultural stereotypes used in the media • interpret images in the media (such as typography, graphic design, infographics, photography, TV, computer, internet) in technical, historical, cultural, ethical and critical aspects.

		NUMBER	PERCENTAGE
Assessment	Midterm Exam	1	70
	Homework	1	30
		Total	100
	Contribution of Final Examination to Overall Grade		60
	Contribution of In-Term Studies to Overall Grade		40
		Total	100

Code	Subject
MED 628	**Healthy Living: The Milestones of the Life for Performance Management**
Goals	This course aims to support fitness practices & dietary habits of healthy life style for medical students. To introduce techniques for reducing stress with healthy living habits. To highlight the importance of superior physical and mental health status for a better job performance.
Content	In the content of this course; understanding physiology of the physical activities, risks and benefits of the regular physical activities, using fitness training as a treatment technique, effects of physical activities to reduce stress, the relation between dietary habits and health will have quite importance.
Course Learning Outcomes	At the end of this course, the student should be able to • explain main exercise physiology • define main fitness terms • analyze main risks and benefits of exercising • relate health and eating habits • perform main fitness training techniques • manage the basic exercises necessary for healthy life • perform physical techniques which are frequently used in stress management • explain the relationship between health and nutrition • describe the principles of healthy eating • recognize exercise as a treatment method for common diseases in the community

		NUMBER	PERCENTAGE
Assessment	Midterm Project	1	25
	Homework	1	25
	Final Project	1	50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

Code	Subject
MED 629	**Music and Medicine**
Goals	This course aims to convey the past and current uses and utilities of music in medicine.
Content	The connection of music and medicine throughout the historical development of antiquity and Middle Ages up until today. The place of music in medical practice after the transformations in the Age of Enlightenment and beyond.
Course Learning Outcomes	At the end of this course, the student should be able to • explain the uses of medicine in the past and present. • describe the uses of music in clinical conditions, and before and after surgical treatment. • explain the effects of music before and after surgery • describe the types of music used in music therapy

		NUMBER	PERCENTAGE
Assessment	Midterm	1	25
	Assignments (Homework)	1	25
	Final Exam		50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

Code	Subject
MED 630	**Health Law**
Goals	The aim of the course is that students obtain a legal rationale, take ethical decisions from a legal perspective, act in a respectful way to patients' rights, legal risks and responsibilities.
Content	The basic concepts of law will be introduced with a view towards health law. The legal nature of medical interventions, concepts of malpractice and complication will be explained. The fundamentals and consequences of legal and criminal liability will be emphasized and medical interventions showing ethical, and legal characteristics will be evaluated from a legal point of view.
Course Learning Outcomes	At the end of this course, the student should be able to • analyze legislature and by-laws related to health law • distinguish branches and consequences of legal responsibility • in taking decisions about patients, help them to make their own decisions in a proper way by respecting their right to self-determination and their privacy. • take ethical decisions from a perspective of patients' rights and legal responsibility • identify legal risks in the developing areas of health law

		NUMBER	PERCENTAGE
Assessment	Assignment / presentation	1	50
	Final EXAM	1	50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

Code	Subject
MED 631	**Creative Drama II**
Goals	This course aims the development of body awareness, improvement of communication skills of students by creating an atmosphere where the students can explore the potential of their emotional intelligence.
Content	In this class, the students will be searching for their abilities for self-representation and being visible in society and going into an active learning process by experiencing image theatre, invisible theatre, newspaper theatre and forum theatre techniques
Course Learning Outcomes	At the end of this course, the student should be able to • build supportive relationships in group by improving personal cooperating skills. • recognize personal awareness, • explain and review the schemes of personal attitude, thought and feeling by playing games and different roles. • improve critical and creative ways of thinking skills, also improve skills for life-long learning which will be useful for professional life as well as personal life. • explore being visible and expressing oneself in front of spectators using games and storytelling techniques.

Assessment		**NUMBER**	**PERCENTAGE**
	Midterm	1	25
	Performance evaluation	5	25
	Final EXAM		50
		Total	100
	Contribution of Final Examination to Overall Grade		50
	Contribution of In-Term Studies to Overall Grade		50
		Total	100

EXAM RULES

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
- **Signature** – Students must sign their multiple-choice answer sheets and/or written-answer sheets.

- **Other Activities Requiring Disciplinary Action**-
    - Students must not give or receive Asstance of any kind during the exam.
    - Gaining access to exam questions before the exam.
    - Using an unauthorized calculator or other mechanical aid that is not permitted.
    - Looking in the exam book before the signal to begin is given.
    - Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given.
    - Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired.
    - Having access to or consulting notes or books during the exam.
    - Looking at or copying from another student's paper.
    - Enabling another student to copy from one's paper.
    - Talking or otherwise communicating with another student during the exam or during the read through period.
    - Disturbing other students during the exam.
    - Consulting other persons or resources outside the exam room during the exam.
    - Copying questions or answers either on paper or with an electronic device to take from the exam room.
    - Taking an exam book or other exam materials from the exam room.
    - Taking an exam in place of another student.
    - Arranging to have another person take an exam for the student.
    - Disobeying to the conduct of supervisor during the exam.
    - Disclosing the contents of an exam to any other person.
    - Failing to remain in the exam room for a given period of time by the supervisors.
    - Failing to follow other exam instructions.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students (published in the Official Journal on August 18th, 2012). The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may loose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.

COURSE LOCATIONS

COURSE CODES	COURSE NAMES	LOCATIONS
MED 302	INTRODUCTION to CLINICAL SCIENCES	**Lectures/Sessions/Panels:** Room Number: B311, Base Floor, Medical Faculty Block, Yeditepe University Campus. **Microbiology Laboratory:** Room Number: 934, 5th Floor, Medical Faculty Block, Yeditepe University Campus. **Pathology Laboratory:** Room Number: 929-930, 5th Floor, Medical Faculty Block, Yeditepe University Campus.
MED 303	INTRODUCTION to CLINICAL PRACTICE	**ICP-CSL:** Room Number: 442, Base Floor, Medical Faculty Block, Yeditepe University Campus. **YH:** Yeditepe University Hospital.

Yeditepe University Campus Address: İnönü Mah. Kayışdağı Cad. 26 Ağustos Yerleşimi, 34755, Ataşehir, İstanbul.

Yeditepe University Hospital Address: İçerenköy Mah. Hastane Yolu Sok. No:102-104. Ataşehir, İstanbul.

* Elective courses locations will be announced later.

SPECIFIC SESSIONS / PANELS

Introductory Session

Aim of the session:
The session provides basic information about Yeditepe University Faculty of Medicine Undergraduate Medical Education Program (YUFM/UG-ME) and the educational phase relevant to the students. This session orients the students to the program and the phase.

Objectives of the Session:
1. To provide basic information about the YUFM/UG-ME.
2. To provide basic information about the phase.
3. To provide essential information on social programs and facilities.

Rules of the Session:
1. The session will be held in two types, conducted by Phase Coordinator and Committee Coordinator, respectively.
2. The first type will be held once in the first week of the educational phase. The second type will be held at the beginning of each committee.
3. Students should attend the session.

Implementation of the Session:
In the first type, Phase Coordinator will present brief information on the following topics:
- Organizational Chart of Yeditepe University Faculty of Medicine Undergraduate Program (YUFM/UG-ME), Work Descriptions and Introduction of Committees Members,
- Directives on YUFM/UG-ME,
- YUFM/UG-ME Program Outcomes
- Learning Objectives of the Phase
- Academic Program of the Phase
- Teaching and Learning Methods
- Learning Environments and Sources/Resources
- Attendance
- Elective Courses (only in Phase I and Phase II)
- Assessment Procedure
- Grade Point Average, Cumulative Grade Point Average (GPA, cGPA) Calculation
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

In the second type, Committee Coordinator will present brief information on the following topics:
- Learning Objectives of the Committee
- Academic Program of the Committee
- Teaching and Learning Methods
- Learning Environments and Sources/Resources, References
- Attendance
- Assessment Methods and Question Distribution Table
- Committee Score Calculation Method
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

Committee Evaluation Session

Aim of the Session:

The aim of the session is to evaluate the committee educational program, with all its components, by the students and the committee coordinators. This session will contribute to the improvement of the educational program in general by giving the opportunity to identify the strengths of the committee educational program and revealing the areas which need improvement.

Objectives of the Program Evaluation Session are to;

- establish a platform for oral feedbacks in addition to the systematically written feedback forms
- give the opportunity to the students and the coordinators to discuss the committee period face to face
- allow the students to review the committee exam questions together with faculty members.

Process:

The total duration of the session is 90 minutes and the session consists of two parts. The first part (30 minutes) is dedicated to oral feedback by the students. All of the oral feedback will be recorded and reported by the committee coordination team. In the second part (60 minutes) committee exam questions will be reviewed and discussed by students and faculty.

Rules of the Committee Evaluation Session:

1. The **Committee Evaluation Session** will be held on the last day of each committee after the committee exam.
2. Students are required to attend the session.
3. The Committee coordinator will lead the session.
4. The faculty members who had contributed questions in the committee exam should attend the session.
5. Students must comply with the feedback rules while giving verbal feedback and all participants shall abide by rules of professional ethics.

Committee Improvement Session

Aim:

The aim of this session is sharing the program improvements based on the evaluation of the educational program data, with the students and the faculty members.

Objectives:

1. To share the improvements within educational program with the students and the faculty members.
2. To inform the students and the faculty members about the processes of the program improvement
3. To encourage student participation in the program improvement processes.

Rules:

1. Program improvements session will be implemented once a year. The implementation will be performed at the begining of the spring semester.
2. Students are required to attend the session.
3. The phase coordinator will monitor the session. If necessary the dean, vice deans and heads of the educational boards will attend to the session.
4. All faculty members will be invited to the session.

Implementation:

Before the Session

1. Phase coordinator will report the results of the improvements of the educational program.
2. The program improvements report has three parts. The first part of the report includes improvements that have been completed, and those that are currently in progress. The second part of the report includes, improvements that are planned in medium term, and the third part of the report includes, improvements that are planned in the long term.
3. The program improvements report also includes the program evaluation data (student feedbacks, faculty feedbacks, results of the educational boards meetings etc.) in use of improvements.

During the Session

4. The phase coordinator will present the program improvements report to the students and the faculty members.
5. Students can ask questions about, and discuss, the results of the program improvement.

Process: The total period of session is 30 minutes and has two parts. The first part (15 minutes) covers, presenting of the program improvement report. The second part (15 minutes) covers, students' questions and discussion.

After the Session

6. The program improvement brief will be published on the website of Yeditepe University Faculty of Medicine (http://med.yeditepe.edu.tr).

Multidisciplinary Case Discussion Panel

Aim:
The aim of this instructional method is, to integrate what students learnt during committee, to fit in the clinical context and to promote deep learning.

Objectives:
1. To relate learning objectives of the committee,
2. To relate clinical cases and learning subjects,
3. To explain learning objectives in the resolution of clinical cases,
4. To value the importantance of multidisiplinary study in the resolution of clinical cases.

Implementation:

Before the Panel
1. Case/cases that will be discussed in the panel will be chosen by a multidisiplinary team, in compliance with committee learning objectives.
2. The resources to analyse the cases will be specified by multidisiplinary team.
3. Students can get hard copies of the cases and the list of sources from student affairs at the beginning of the committee.
4. Students shall study cases in the context of learning objectives before the panel.
5. Before the panel, students may consult the faculty members for information about cases.

During the Panel
6. Cases will be shared visually with students by the multidisiplinary team.
7. Possible resolution of cases will be shared and discussed with students by the multidisiplinary team.
8. After the resolution of cases, students can ask questions to faculty members about the commitee learning obcetives in the context of cases.

Process: The total duration of the Panel is 60 minutes and has 2 parts. The first part (40 minutes), covers the presentation of cases, resolution of cases, asking questions to students and discussion as suitable to learning objectives during the resolution by multidisiplinary team. The second part (20 minutes), covers students' questions and discussion.

After the Panel
9. Students may continue reviewing the cases in the context of committee learning objectives.
10. The multidisiplinary team will review the usefulness of cases as a learning tool in the context of committee learning objectives. "The Panel Report" will be written by the multidisiplinary team.

INDEPENDENT LEARNING

Description:
"Independent learning" is a process, a method and a philosophy of education in which a student acquires knowledge by his or her own efforts and develops the ability for inquiry and critical evaluation. It includes freedom of choice in determining one's learning objectives, within the limits of a given project or program and with the aid of a faculty adviser. It requires freedom of process to carry out the objectives, and it places increased educational responsibility on the student for the achieving of objectives and for the value of the goals (1).

Aim:
The aim of this instructional strategy is to develop the students' ability, to learn individually, so they are prepared for the classroom lessons, lectures, laboratory experiences and clinical practices, exams, professional life and have the abilities needed for lifelong learning.

Objectives:
With this instructional strategy, students will develop;

- the skills that will help them to learn independently.
- self-discipline in their work habits.
- their evidence based research skills by using reliable resources.
- their teamwork skills by studying together.
- their clinical skills as self-directed working in the clinical skills laboratory.

Rules:
1. All of the students will define independent learning process according to below algorithm.
2. All of the students will be required to fill out a form, which is a self-assessment form for the independent learning (methodology: timing, sources, strategy, etc.).
3. The students' academic performance and independent learning methodology will be analyzed comparatively, and feed-back on further improvements will be provided.

What a student should do for learning independently?
1. **Analyzing:** First you will need to analyze carefully, what your problems and weaknesses are. For example, if you are studying anatomy, is your weak area broadly upper limb, lower limb, or what?
2. **Addressing:** Once you've decided your specific problems, you can list them. Which one needs to be addressed urgently? Work out your priorities. Whatever your subject area is, don't be afraid to return to the basics if necessary. It may give you more confidence in the long run to ensure you have a proper understanding of basic concepts and techniques.
3. **Accessing:** If you need reliable information, or if you need to read about a subject and put it into context, a textbook may be the best place to start. However, the Internet may be helpful if you need very up-to-date information, specific facts, or an image or video etc. If you need an academic research article, reports or case studies for your topic, then a database (Pubmed etc.) would be the best option.
4. **Timing:** In the weekly syllabus you will see, a specific time called "independent learning hour" for your independent work. In addition to these hours, the students should also have their own time schedule for their study time at home.
5. **Planning:** Your next step will be to work out a realistic study-plan for your work. What goals could you literally set for yourself? Don't make them too ambitious but set minor goals or targets that you know you will be able to achieve without having to spend a very long time working on them. How many hours will you need to achieve them? How will you know when you've achieved them?
6. **Recording:** When you work independently, it's a good idea to keep a written record of the work you've done. This can help with further planning and also give a sense of achievement as well as provide something to include in a progress file. As time goes by you may surprise yourself with what you've been able to achieve. This could motivate you to keep going, as could increase your confidence, and even improve your results
7. **Reflecting:** Reflecting on what you've done can help you decide whether the activity was really effective, whether an alternative approach might be better on another occasion, whether you spent the right amount of time and whether you have achieved the target you'd set yourself.
8. **Improving:** Once you've achieved the target, the process of planning can start again. Your needs and priorities may have changed, so think about them and then set yourself to another target.

Reminder: For further information about the independent learning, please contact the Department of Medical Education.

Reference:

1. Candy, P. (1991) Self-direction for lifelong learning: a comprehensive guide to theory and practice. San Francisco: Jossey Bass.

For further reading useful resources to recommend to students:

- Burnapp, D. (2009). Getting Ahead as an International Student. London: Open University Press.
- Marshall, L. & Rowland, F. (1998) A Guide to learning independently. London: Open University Press.
- University of Southampton / UKCISA online resource 'Prepare for Success'

ASSESSMENT PROCEDURE

The Assessment Procedure of the Phase III covers exams and scores and their abbrevations that shown below.

- Exams:
  - Committee Exam (CE)
  - Mid-term Exam (MTE)
  - Final Exam (FE)
  - Incomplete Exam (ICE)
  - Make-up Exams (MUE)
- Scores*:
  - Committee Score (CS)
  - Committees Mean Score (CMS)
  - Introduction to Clinical Practice Score (ICPS)
  - Scientific Research and Project Course Score (SRPCS)
  - Final Exam Score (FES)
  - Incomplete Exam Score (ICES)
  - Term Score (TS)

* All scores have a range of 0-100 points.

Assessment approaches, assessment methods and assessment tools, that related with the exam and score types, are shown in below table.

Assessment Approaches	Assessment Methods	Question Types / Assessment Tools	Exams	Derived Scores
Knowledge-based Assessment	WE: Written Examination	MCQ: Multiple Choice Questions	CE, MTE, FE, ICE	CS, ICPS, FES, ICES
		EMQ: Extended Matching Questions	CE	CS
		FSAQ: Fill-in-the-Blank Short Answer Questions	MuE	CS
Competency–based Assessment	OSCE: Objective Structured Clinical Examination	OSCE Checklist		ICPS
Performance–based Assessment	PWPE: Project Writing and Presenting Evaluation	PWPE Checklist		SRPCS

Exams Information (MED 302, MED 303)	
CE	For the proportional correspondence of individual learning objectives, please see the committee's assessment matrix table/page.
FE	FE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
ICE	ICE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
MUE$_{ICS}$	MUE will be held only twice in a term. MUE consists of FSAQs. MUE content will be developed by the coordination committees.

Scores Information (MED 302, MED 303)	
CS	The committee score is based on various question types/numbers and/or assessment tools (MCQ, EMQ, MEQ or Checklists). Please see the committee's assessment matrix table/page for the specifications.
CMS	= Average of CSs
ICPS	= (50% OSCE1) + (50% OSCE2)
SRPCS	= Score information is shown in below Scientific Research and Project Course - III page.
FES	= Final Exam Score
ICES	= Incomplete Exam Score
TS *for students, who are exempted from FE*	= 98% of CMS + 2% of SRPCS
TS *for students, who are not exempted from FE*	= 98% of (60% of CMS + 40% of FES or ICES) + 2% of SRPCS

Pass or Fail Calculations of the Courses
INTRODUCTION to CLINICAL SCIENCES (ICS) III (MED 302)
Pass; *TS* **≥ *50***
Fail; *FES* **< *50*** *(barrier point), ICES* **< *50*** *(barrier point), or/and TS* **< *50***
The student is exempted from FE, if the CMS is **≥ *75*** *and all CSs are* **≥ *50***
The FE and ICE barrier point is not applied to the students whose all CSs are **≥ *50***
INTRODUCTION to CLINICAL PRACTICE (ICP) III (MED 303)
Pass; *ICPS* **≥ *50***
Fail; *ICPS* **< *50***

The Assessment Procedure of the Phase III will be announced and explained in the introductory session at the beginning of the academic year.

Definitions of the Assessment Methods and Question Types

MCQ consist of a question, followed by five plausible alternative responses from which the student has to select the correct one.

EMQ are similar to multiple choice questions but with one key difference, that they test knowledge in a far more applied, in depth, sense. EMQ is based on a single theme, two or more questions and has a long option list.

MEQ is made up of one or more short answer questions. The student is provided with basic science or clinical information and then asked to write brief responses to one or more questions. When a series of questions is presented, additional information about the original problem can be provided at each subsequent step, guiding the students through an analytical process.

FSAQ, Fill-in-the-Blank Short Answer Questions are typically composed of a brief prompt that demands a written answer that varies in length from one or two words to a sentence.

OSCE describes a form of competency-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat simulated patients who present with some type of medical problem.

ACADEMIC CALENDAR of PHASE III 2019 - 2020

INTRODUCTION to CLINICAL SCIENCES (MED 302)

COMMITTEE I

INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEMS (7 Weeks)

Beginning of Committee	September 9, 2019	Monday
End of Committee	October 25, 2019	Friday
Committee Exam	**October 25, 2019**	**Friday**

COMMITTEE II

CARDIOLOGY and RESPIRATORY SYSTEM (7 Weeks)

Beginning of Committee	October 28, 2019	Monday
End of Committee	December 13, 2019	Friday
Committee Exam	December 13, 2019	**Friday**

National Holiday	**October 28$^{1/2}$, 2019** **October 29, 2019**	**Monday, Tuesday**
Commemoration of Atatürk	**November 10, 2019**	**Sunday**

COMMITTEE III

GASTROINTESTINAL SYSTEM (4 Weeks)

Beginning of Committee	December 16, 2020	Monday
End of Committee	January 10, 2020	Friday
Committee Exam	**January 10, 2020**	**Friday**

New Year	**January 01, 2020**	**Wednesday**

COMMITTEE IV

ENDOCRINE, REPRODUCTIVE and URINARY SYSTEM (8 Weeks)

Beginning of Committee	January 13, 2020	Monday
End of Committee	March 20, 2020	Friday
Committee Exam	**March 20, 2020**	**Friday**

MIDTERM BREAK	**January 20 – January 31, 2020**	
Physicians' Day	**March 14, 2019**	**Saturday**

COMMITTEE V

NERVOUS SYSTEM and PSYCHIATRY (7 Weeks)

Beginning of Committee	March 23, 2020	Monday
End of Committee	May 8, 2020	Friday
Committee Exam	**May 8, 2020**	**Friday**

National Holiday	**April 23, 2020**	**Thursday**
Labour's Day	**May 01, 2020**	**Friday**

COMMITTEE VI
MUSCULOSKELETAL SYSTEM (5 Weeks)

Beginning of Committee	May 11, 2020	Monday
End of Committee	June 12, 2020	Friday
Committee Exam	**June 12, 2020**	**Friday**
National Holiday	**May 19, 2020**	**Tuesday**
Religious Holiday	**May 23$^{1/2}$ – 26, 2020**	**Saturday-Tuesday**

SCIENTIFIC RESEARCH and PROJECT COURSE

Midterm Assesment	**Jan 17,2020**	**Friday**
Final Assesment	**May 15,2020**	**Frdiay**

INTRODUCTION to CLINICAL SCIENCES (MED 302):

Make-up Exam	**June 22, 2020**	**Monday**
Final Exam	**July 3, 2020**	**Friday**
Incomplete Exam	**July 24, 2020**	**Friday**

INTRODUCTION to CLINICAL PRACTICE – III (MED 303):

Beginning of ICP - III	October 1, 2019	Tuesday
End of ICP - III	May 22, 2019	Friday
Midterm Exam (OSCE-I)	**February 18-19, 2020**	**Tuesday-Wednesday**
Make-up Exam	**May 22, 2020**	**Friday**
Final Exam (OSCE-II)	**June 15-16, 2020**	**Monday - Tuesday**
Incomplete Exam	**July 1, 2020**	**Wednesday**

FREE ELECTIVE COURSES:

Beginning of Elective Courses	February 7, 2020	Friday
End of Elective Courses	May 22, 2020	Friday
Midterm Exam	**March 27, 2020**	**Friday**
Make-up Exam	**May 29, 2020**	**Friday**
Final Exam	**June 5, 2020**	**Friday**
Incomplete Exam	**June 18, 2020**	**Thursday**
1. Coordination Committee Meeting	October 18, 2019	**Friday**
2. Coordination Committee Meeting	January 14, 2020	**Tuesday (with student participation)**
3. Coordination Committee Meeting	May 12, 2020	**Tuesday (with student participation)**
4. Coordination Committee Meeting	July 21, 2020	**Tuesday**

RECOMMENDED TEXTBOOKS

Biomedical Ethics & Deontology
1. Marcia Lewis, Carol D. Tamparo. Medical Law, Ethics, & Bioethics for the Health Professions, F.A. Davis Publishing House, 2012, ISBN: 0803627068
2. Michael Boylan. Medical Ethics, Wiley-Blackwell Publishing House, 2013, ISBN: 978-1118494752

Biostatistics
1. Pagano, Marcello, Gauvreau, Kimberlee. Principles of Biostatistics. Duxbury Press, 2000 ISBN 0534229026, 9780534229023.
2. Glantz, Stanton A. Primer of Biostatistics. 7th Edition. McGraw Hill Professional, 2011. ISBN 0071447814, 9780071447812.

Infectious Diseases and Clinical Microbiology
1. Murray, Patrick R, Rosenthal, Ken S, Pfaller, Michael A.. Medical Microbiology with STUDENT CONSULT Online Access. 8th Edition, 2016.

Medical Genetics
1. Turnpenny, Peter D, Ellard, Sian. Emery's Elements of Medical Genetics. 14th Edition. Churchill Livingstone, 2012, ISBN: 9780702040436

Neurosurgery
1. Microneurosurgery, Volume I to Volume V, Thieme Kindle Edition by Mahmut Gazi Yasargil (Author)
2. Neurology and Neurosurgery Illustrated, 5th Edition by Kenneth W. Lindsay PhD FRCS (Author), Ian Bone FRCP FACP (Author), Geraint Fuller MD FRCP (Author)
3. Handbook of Neurosurgery Feb 22, 2010 by Mark S. Greenberg

Pharmacology
1. Harvey, Richard A. Lippincott's Illustrated Review of Pharmacology. 6th ed., Wolters Kluwer Health, 2015. ISBN: 978-1469887562.
2. Katzung, Bertram G., Masters, Susan B., Trevor Anthony J. Katzung's Basic & Clinical Pharmacology. 14th Edition. McGraw Hill Companies, 2017. ISBN: 978-1259641152.
3. Brunton, Laurence, Chabner, Bruce, Knollman, Bjorn. Goodman&Gilman's The Pharmacological Basis of Therapeutics. 13th Edition. McGraw Hill Companies, 2017. ISBN: 978-1259584732.

Orthopedic Surgery
1. Ortopedik Fizik Muayane, çeviri ed. Uğur Şaylı, Güneş Tıp Kitapevi
2. Review of Orthopaedics, 6th edition (ed. Mark D. Miller)
3. AAOS Comprehensive Orthopaedic Review, 2nd edition (ed. Martin I. Boyer)

Pathology
1. Abbas Aster, Kumar. Robbıns Basıc Pathology. 9th edition, Saunders, Elsevıer Inc. 2013. ISBN:978-0-8089-2432-6

Psychiatry
1. Öztürk O. Ruh Sağlığı ve Bozuklukları. 2. Baskı, Ankara 2011. ISBN: 9786058617292
2. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9. Ed. 2009, Lippincott Williams & Wilkins, PA, USA. ISBN: 9780781768993
3. Purves D, Augustine GJ. Fitzpatrick D. et al. Neuroscience. 5. Ed. 2012, Sinauer Assoc, Mass, USA. ISBN: 9780878936953

General Surgery
1. Brunicardi, F. Schwartz's Principles of Surgery, 10th edition, July 16, 2014, ISBN: 0071796754 / 9780071796750

Urology
1. Campbell-Walsh Urology, 11th Edition 4-Volume Set. By Alan J. Wein, MD, FACS, PhD (hon), Louis R. Kavoussi, MD, Alan W. Partin, MD, PhD and Craig A. Peters, MD, FACS, FAAP. Imprint: Elsevier. ISBN: 978-1-4557-7567-5. Copyright: 2016

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

DISTRIBUTION of LECTURE HOURS

September 9, 2019 - October 25, 2019

COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	INFECTIOUS DISEASES	ID	20				**20**
	MEDICAL MICROBIOLOGY	MM	10		2 X 1=2 (4 Groups)		**12**
	PHARMACOLOGY	PC	21				**21**
	PATHOLOGY	PT	12			2	**14**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	12				**12**
	HEMATOLOGY	HEM	11				**11**
	PUBLIC HEALTH	PH	8				**8**
	IMMUNOLOGY	IMM	6				**6**
	MEDICAL GENETICS	MG	5				**5**
	PEDIATRICS	PED	4				**4**
	PATHOPHYSIOLOGY	PP	4				**4**
	PHYTOTHERAPY	PHY	3				**3**
	BIOSTATISTICS	BS	3				**3**
	ONCOLOGY	ONC	3				**3**
	FAMILY MEDICINE	FM	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		124		2	4	**130**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				2	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			2 X 3=6 (4 Groups)		**6**
TOTAL			**124**		**8**	**6**	**138**
	INDEPENDENT LEARNING						**107**

Coordination Committee

HEAD	Meral Sönmezoğlu, MD, Prof.
SECRETARY	Ayşegül Kuşkucu, MD, Assist. Prof.
MEMBER	Ece Genç, PhD, Prof.
MEMBER	Ferda Özkan, MD, Prof.
MEMBER	Atilla Özkan, MD, Assoc. Prof.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD, Prof. Çağrı Büke, MD, Prof.
MEDICAL MICROBIOLOGY	İ. Çağatay Acuner, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
PATHOLOGY	Aydın Sav, MD, Prof. Şevket Ruacan, MD, Prof.
HEMATOLOGY	Atilla Özkan, MD, Assoc.Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof S. Perihan Saf, MD
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, Assoc. Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Assist Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof. M. Engin Celep, PhD, Assist. Prof.
ONCOLOGY	Okan Kuzhan, MD, Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Mustafa Ferudun Çelikmen, MD, Assist. Prof. Pınar Tura, MD, Assist. Prof. Zeynep Alkan, MD, Assoc. Prof. Serdar Özdemir, MD, Assist. Prof. Mustafa Yazıcıoğlu, MD. Assist. Prof. Cem Şimşek, MD. Assist. Prof. Gökhan Gencer, MD. Assist. Prof. Merve Ekşioğlu, MD. Deniz Gürsoy, MD. Fırat Demircan, MD.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
AIMS and LEARNING OBJECTIVES

INFECTIOUS DISEASES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. ***to convey*** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. ***to convey*** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. ***to convey*** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. ***to convey*** biostatistical knowledge required in design of medical research,
10. ***to convey*** necessary knowledge on genetical basis of clinical conditions,
11. ***to equip with*** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***explain*** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2.0. ***recall*** structures, and
2.1. ***explain*** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3.0. ***classify*** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,

4.0. ***explain*** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

5.0. ***explain*** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

6.0. ***explain*** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

7.0. ***explain*** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,

8.0. ***explain*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

9.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:

9.1. practice of history taking and physical examination
9.2. evaluation of emergency case (sepsis and septic shock)
9.3. approach to healthy individual or patient (fever)
9.4. laboratory tests/examinations (urine sample collection, urine strip/dipstick test, urine culture)
9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases)
9.6. point of care testing (urine strip/dipstick test)
9.7. making preliminary diagnosis or definitive diagnosis decision
9.8. making non-intervention or intervention decision
9.9. practicing non-intervention or intervention
9.10. referral/transport of healthy individual or patient

10.1.***list*** goals and principles of drug use,

10.2.***describe*** effects,

10.3.***explain*** mechanism of action (pharmacodynamics),

10.4.***list*** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug inreactions and side effects,

10.5.***explain*** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

11.0. ***explain*** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,

12.0.***define*** approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,

13.0. ***explain*** hereditary immune system disorders,

14.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

15.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
16.0. ***perform*** basic clinical skills, practiced on phantom models (suturing technique), required at primary health care service level.

HEMATOPOIETIC SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of hematopoietic system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. ***to convey*** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. ***to convey*** basic knowledge on phytotherapy
10. ***to convey*** knowledge on comparative biostatistical analysis of study groups,

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

H1. ***recall*** anatomy, histology and physiology of hematopoietic system,
H2. ***explain*** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
H3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
H4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
H5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
H6. at multi-system level and/or related to hematopoietic system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

H6.1. practice of history taking and physical examination
H6.2. evaluation of emergency case
H6.3. approach to healthy individual or patient (anemia, lymphadenopathy)
H6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests, hematology tests for anemia)
H6.5. imaging tests/examinations (nuclear medicine tests in hematology)
H6.6. point of care testing (hematology-peripheral blood smear examination, hematology-complete blood count)
H6.7. making preliminary diagnosis or definitive diagnosis decision
H6.8. making non-intervention or intervention decision
H6.9. practicing non-intervention or intervention
H6.10. referral/transport of healthy individual or patient
H7. ***classify*** blood products and blood groups,
H8. ***define*** principles of transfusion,
H9. ***explain*** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
H10. ***explain*** mechanisms of bone marrow toxicity of drugs and other chemicals,
H11. ***list*** principles of cancer chemotherapy,
H12. ***explain*** chemotherapy in leukemia and lymphoma,
H13. ***list*** phytotherapeutic agents with immunomodulatory effects,
H14. ***list*** principles of comparative biostatistical analysis of study groups,
H15. ***explain*** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0 -12.0, H7, H8	ID	M. Sönmezoğlu A. Ç. Büke	14	6	6	26
1.0 -12.0	MM	İ. Ç. Acuner	7	3	3	13
10.0, H9, H10	PC	E. Genç E.N. Özdamar	15	4	4	23
4.0.,5.0, H2	PT	A. Sav Ş. Ruacan	9	4	4	17
14.0	BED	E. Vatanoğlu Lutz	9	4	4	17
H1 – H7	HEM	H. A. Özkan	8	3	3	14
6.0.,7.0.,11.0.,12.0.	PH	R. E. Sezer H. A.Taşyıkan	6	2	2	10
4.0, 5.0, 13.0	IMM	G. Y. Demirel	4	2	2	8
14.0.	MG	A. Ç. Kuşkucu	4	2	2	8
8.0.,9.0., 9.1.	PED	S. Kemahlı P. Saf	4	2	2	8
4.0.,5.0.,8.0, H1, H2	PP	M. Kaçar	2	1	1	4
H13 – H15	PHY	E. Yeşilada	2	1	1	4
15.0., H14	BS	Ç. Altunok	2	1	1	4
H2, H11, H12	ONC	O. Kuzhan	2	1	1	4
9.0, 11.0	FM	G. İzbırak	1	0	0	1
9.2	EM	M. F. Çelikmen	1	0	0	1
TOTAL			90	36	36	162
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
1.0 -12.0, H7, H8	IDCM	M. Sönmezoğlu	2	-	-	2
10.0, H9, H10	PC	E. Genç	1	-	-	1
H1 – H7	HEM	H. A. Özkan	1	-	-	1
4.0.,5.0, H2	PT	A. Sav	1	-	-	1
		TOTAL	5	-	-	5

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

****39** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM

WEEK I / 9 - 13 Sep 2019

	Monday 9-Sep-2019	Tuesday 10-Sep-2019	Wednesday 11-Sep-2019	Thursday 12-Sep-2019	Friday 13-Sep-2019
09.00- 09.50	**Introduction to Phase III**	**Lecture** Beneficence and Non-Maleficence E. Vatanoğlu Lutz	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I İ.Ç. Acuner	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Laboratory Diagnosis of Infectious Diseases I İ.Ç. Acuner	**Lecture** Transplantation E. Vatanoğlu Lutz	**Lecture** Antimicrobial Agents: Mechanisms of Resistance II İ.Ç. Acuner		
11.00- 11.50	**Lecture** Laboratory Diagnosis of Infectious Diseases II İ.Ç. Acuner	**Lecture** Principles of Autonomy and Informed Consent E. Vatanoğlu Lutz	**Lecture** Introduction to Antimicrobial Chemotherapy E. Genç		
12.00- 12.50	**Lecture** Laboratory Diagnosis of Infectious Diseases III İ.Ç. Acuner	**Lecture** Justice in Medicine E. Vatanoğlu Lutz	**Lecture** ß Lactam Antibiotics I E. Genç		
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to the Course I E. Vatanoğlu Lutz	**Lecture** Laboratory Diagnosis of Infectious Diseases IV İ.Ç. Acuner	**Lecture** ß Lactam Antibiotics II E. Genç	**Lecture** Public Health and Communicable Diseases-I R.E. Sezer	**Independent Learning**
15.00- 15.50	**Lecture** Introduction to the Course II E. Vatanoğlu Lutz	**Lecture** Laboratory Diagnosis of Infectious Diseases V İ.Ç. Acuner	**Lecture** Vancomycin & Other Cell Wall Synthesis Inhibitors E. Genç	**Lecture** Public Health and Communicable Diseases-**II** R.E. Sezer	
16.00- 16.50	**Lecture** Physician-Patient Relationship E. Vatanoğlu Lutz	**Lecture** Antimicrobial Agents: Basic Concepts & Principles I İ.Ç. Acuner	**Independent Learning**	**Independent Learning**	
17.00-17.50	**Lecture** Confidentiality and Truthfulness E. Vatanoğlu Lutz	**Lecture** Antimicrobial Agents: Basic Concepts & Principles II İ.Ç. Acuner	**Independent Learning**	**Independent Learning**	

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK II / 16-20 Sep 2019

	Monday 16-Sep-2019	Tuesday 17-Sep-2019	Wednesday 18-Sep-2019	Thursday 19-Sep-2019	Friday 20-Sep-2019
09.00- 09.50	**Lecture** Pathophysiology of Infectious Diseases I M. Kaçar	**Lecture** Hospital Infection M. Sönmezoğlu	**Lecture** Pathophysiology of Infectious Diseases III M. Kaçar	**Independent Learning**	**Lecture** Aminoglycosides E. Genç
10.00- 10.50	**Lecture** Pathophysiology of Infectious Diseases II M. Kaçar	**Lecture** Febril Neutropenia M. Sönmezoğlu	**Lecture** Pathophysiology of Hematopoietic System Disorders I M. Kaçar		**Lecture** Sulfonamides, Chloramphenicol & Tetracyclines E. Genç
11.00- 11.50	**Lecture** Pathology of Mycobacterial Infections A. Sav	**Lecture** Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu	**Lecture** Phytotherapy I E. Yeşilada		**Lecture** Prevention and Control of Communicable Diseases I R.E. Sezer
12.00- 12.50	**Lecture** Antimycobacterial Drugs E. Genç	**Lecture** Infections in Immuncompromised Host M. Sönmezoğlu	**Lecture** Phytotherapy II E. Yeşilada		**Lecture** Prevention and Control of Communicable Diseases II R.E. Sezer
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Zoonotic Diseases I M. Sönmezoğlu	**Lecture** Planning Medical Studies I Ç. Altunok	**Lecture** Phytotherapy III E. Yeşilada	**Independent Learning**	**Independent Learning**
15.00- 15.50	**Lecture** Zoonotic Diseases II M. Sönmezoğlu	**Lecture** Planning Medical Studies II Ç. Altunok	**Lecture** Occupational Health Hazards I A.Ç. Büke		
16.00- 16.50	**Lecture** Fungal and Parasitic Skin and Soft Tissue Infections M. Sönmezoğlu	**Lecture** Research Design Ç. Altunok	**Lecture** Occupational Health Hazards II A.Ç. Büke		
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Vaccines A.Ç. Büke		

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK III / 23-27 Sep 2019

<table>
<tr><th></th><th>Monday
23-Sep-2019</th><th>Tuesday
24-Sep-2019</th><th>Wednesday
25-Sep-2019</th><th>Thursday
26-Sep-2019</th><th>Friday
27-Sep-2019</th></tr>
<tr><td>09.00- 09.50</td><td>Independent Learning</td><td>Lecture
Non/Hodgkin's Lymphoma I
Ş. Ruacan</td><td>Lecture
Pathology of Myeloproliferative Diseases I
Ş. Ruacan</td><td>Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pathology of Bone Marrow-1
Ş. Ruacan</td><td>Lecture
Non/Hodgkin's Lymphoma II
Ş. Ruacan</td><td>Lecture
Pathology of Myeloproliferative Diseases II
Ş. Ruacan</td><td>Independent Learning</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Pathology of Bone Marrow-2
Ş. Ruacan</td><td>Lecture
Hematostatic Drugs and Hematostatic Blood Products I
E. Genç</td><td>Lecture
Lymphoreactive Disease
Ş. Ruacan</td><td>Lecture
Pathophysiology of Hematopoietic System Disorders II
M. Kaçar</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Hodgkin’s Lymphoma
Ş. Ruacan</td><td>Lecture
Hematostatic Drugs and Hematostatic Blood Products II
E. Genç</td><td>Lecture
Pathology of Spleen
Ş. Ruacan</td><td>Lecture
Pathophysiology of Hematopoietic System Disorders III
M. Kaçar</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Introduction to Anemias in Childhood
S. Kemahlı</td><td colspan="2">Microbiology Laboratory
(Antibacterial Susceptibility Testing)
Microbiology Instructors</td><td colspan="2">Microbiology Laboratory
(Antibacterial Susceptibility Testing)
Microbiology Instructors</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Introduction to Hemolytic Anemias Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others)
S. Kemahlı</td><td>GROUP A</td><td>GRPUP B IL</td><td>GROUP C IL</td><td>GROUP D IL</td><td>GROUP A IL</td><td>GRPUP B IL</td><td>GROUP C</td><td>GROUP D IL</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Hemophilia and other Coagulopathies in Childhood
S. Kemahlı</td><td>GROUP A IL</td><td>GRPUP B</td><td>GROUP C IL</td><td>GROUP D IL</td><td>GROUP A IL</td><td>GRPUP B IL</td><td>GROUP C IL</td><td>GROUP D</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td colspan="2">Independent Learning</td><td colspan="2">Independent Learning</td><td colspan="2"></td></tr>
</table>

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK IV / 30 Sep-4 Oct 2019

	Monday 30-Sep-2019	Tuesday 1-Oct-2019	Wednesday 2-Oct-2019	Thursday 3-Oct-2019	Friday 4-Oct-2019
09.00- 09.50	**Lecture** Transhumanisms and Ethics E. Vatanoğlu Lutz	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Semiology-I A.Ç. Büke
10.00- 10.50	**Lecture** Ethics of the Future/Future of Ethics E. Vatanoğlu Lutz	**ICP-CSL** (Suturing technique) M. F. Çelikmen / C. Şimşek	**ICP-CSL** (Suturing technique) M. Yazıcıoğlu / M. Ekşioğlu	**ICP-CSL** (Suturing technique) C. Şimşek / F. Demircan	**Lecture** Semiology-II A.Ç. Büke
11.00- 11.50	**Lecture** Bioethics E. Vatanoğlu Lutz	**Group A ICP** / **Group B Small Group Study SRPC** / **Group C IL** / **Group D IL**	**Group A IL** / **Group B IL** / **Group C Small Group Study SRPC** / **Group D ICP**	**Group A Small Group Study SRPC** / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Parasitic Infections I A.Ç. Büke
12.00- 12.50	**Lecture** Responsible Biomedical Research E. Vatanoğlu Lutz				**Lecture** Parasitic Infections II A.Ç. Büke
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Ethics of Publication E. Vatanoğlu Lutz	**Lecture** Myeloproliferative Diseases A. Özkan	**Lecture** Plasma Cell Dyscrasias A. Özkan	**Lecture** Quantitative and Qualitative Platelet Disorders A. Özkan	**ICP-CSL** (Suturing technique) P. Türe / G. Gencer
15.00- 15.50	**Microbiology Laboratory** (Diagnostic tests of respiratory specimens) Microbiology Instructors	**Lecture** Chronic Leukemia A. Özkan	**Lecture** Hypercoagulability A. Özkan	**Lecture** Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia A. Özkan	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study SRPC**
16.00- 16.50	GROUP A / GROUP B IL / GROUP C IL / GROUP D IL	**Lecture** Aplastic and Hypoplastic Anemias A. Özkan	**Lecture** Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias A. Özkan	**Lecture** Lymphoma A. Özkan	
17.00-17.50	GROUP A IL / GROUP B	**Lecture** Nutritional Anemias A. Özkan	**Lecture** Introduction to the Program of Family Medicine G. İzbırak	**Lecture** Acute Leukemias A. Özkan	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK V / 7-11 Oct 2019

	Monday 7-Oct-2019	Tuesday 8-Oct-2019	Wednesday 9-Oct-2019	Thursday 10-Oct-2019	Friday 11-Oct-2019
09.00- 09.50	**Case Discussions** Pathology Tissue Response to Infections A. Sav	**ICP** (Ear-Nose-Throat Examination) S. Akbulut / Z. Alkan / S. Özdemir	**Lecture** Introduction to Clinical Oncology I O. Kuzhan	**Independent Learning**	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel
10.00- 10.50	**Case Discussions** General Rewiev of Pathology of Infections Disease A. Sav	Group A IL / Group B IL / Group C Small Group Study SRPC / Group D ICP	**Lecture** Introduction to Clinical Oncology II O. Kuzhan	**ICP** (Ear-Nose-Throat Examination) S. Akbulut / Z. Alkan / S. Özdemir	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel
11.00- 11.50	**Microbiology Laboratory** (DiagnosticTests of Respiratory Specimens) Microbiology Instructors; Group A IL / Group B IL / Group D / Group C IL		**Lecture** Treatment Approaches of Cancer O. Kuzhan	Group A ICP / Group B Small Group Study SRPC / Group C IL / Group D IL	**Lecture** How to Write a Project Report? B. Yılmaz / H. Taşyıkan
12.00- 12.50	Group D IL / Group C	**Lecture** Laboratory Diagnosis of Infectious Diseases VI (Advancements in Diagnostic Microbiology) İ. Ç. Acuner	**Lecture** Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu		**Lecture** Scientific Career and Preparation of CV B. Yılmaz / H. Taşyıkan
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP** (Ear-Nose-Throat Examination) S. Akbulut / Z. Alkan / S. Özdemir	**Lecture** Antiprotozoal Drugs E. N. Özdamar	**Lecture** Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen	**Lecture** Antianemic Drugs E. Genç	**ICP** (Ear-Nose-Throat Examination) S. Akbulut / Z. Alkan / S. Özdemir
15.00- 15.50	Group A IL / Group B IL / Group C ICP / Group D Small Group Study SRPC	**Lecture** Immunomodulators E. N. Özdamar	**Lecture** Introduction to Clinical Genetics A. Ç. Kuşkucu	**Lecture** Antihelminthic Drugs E. Genç	Group A Small Group Study SRPC / Group B ICP / Group C IL / Group D IL
16.00- 16.50		**Independent Learning**	**Lecture** Inherited Immune System Disorders A. Ç. Kuşkucu	**Lecture** Pathology of Viral Infections I A. Sav	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Pathology of Viral Infections II A. Sav	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VI / 14-18 Oct 2019

	Monday 14-Oct-2019	Tuesday 15-Oct-2019	Wednesday 16-Oct-2019	Thursday 17-Oct-2019	Friday 18-Oct-2019
09.00- 09.50	**Lecture** Antimalarial Drugs E. N. Özdamar	**Lecture** Lenforeticular Infections I A.Ç. Büke	**Lecture** Macrolides E. N. Özdamar	**Lecture** Antifungal Drugs E. N. Özdamar	**Independent Learning**
10.00- 10.50	**Lecture** Quinolones E. N. Özdamar	**Lecture** Lenforeticular Infections II A.Ç. Büke	**Lecture** Antiviral Drugs E. N. Özdamar	**Lecture** Antiseptics and Disinfectants E. N. Özdamar	
11.00- 11.50	**Lecture** Investigation of a Disease Epidemic I H.A.Taşyıkan	**Lecture** Tuberculosis & Other Mycobacterial Infections I A.Ç. Büke	**Lecture** Blood Components and Transfusion Indications M. Sönmezoğlu	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	
12.00- 12.50	**Lecture** Investigation of a Disease Epidemic II H.A.Taşyıkan	**Lecture** Tuberculosis & Other Mycobacterial Infections II A.Ç. Büke	**Lecture** Blood Groups M. Sönmezoğlu	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Approach to the Pediatric Patient with Fever P. Saf	**Lecture** Epidemiology of Communicable Diseases I H.A.Taşyıkan	**Multidisciplinary Case Discussion Panel**	**Lecture** Genetics of Oncology I A.Ç. Kuşkucu	**Independent Learning**
15.00- 15.50	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel	**Lecture** Epidemiology of Communicable Diseases II H.A.Taşyıkan	**Multidisciplinary Case Discussion Panel**	**Lecture** Genetics of Oncology II A.Ç. Kuşkucu	
16.00- 16.50	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel	**Lecture** Pharmacological Basis of Cancer Therapy I E. N. Özdamar	**Lecture** Introduction to Clinical Oncology O. Kuzhan	**Independent Learning**	
17.00-17.50	**Independent Learning**	**Lecture** Pharmacological Basis of Cancer Therapy II E. N. Özdamar	**Independent Learning**	**Independent Learning**	

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VII / 21-25 Oct 2019

	Monday 21-Oct-2019	Tuesday 22-Oct-2019	Wednesday 23-Oct-2019	Thursday 24-Oct-2019	Friday 25-Oct-2019
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					
11.00- 11.50					
12.00- 12.50					
13.00 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	COMMITTEE EXAM
15.00- 15.50					
16.00- 16.50					
17.00-17.50					**Program Evaluation Session** Committee I Coordination Committee Members

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

DISTRIBUTION of LECTURE HOURS
October 28, 2019 – December 13, 2019
COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABB.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PHARMACOLOGY	PC	25				**25**
	PATHOLOGY	PT	24	1x3=3 (2 Groups)			**27**
	CHEST MEDICINE	CHM	18				**18**
	CARDIOLOGY	CRD	14				**14**
	PUBLIC HEALTH	PH	8				**8**
	PATHOPHYSIOLOGY	PP	7				**7**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	5				**5**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	4				**4**
	ENT DISEASES	ENT	4				**4**
	BIOISTATISTICS	BS	3				**3**
	THORACIC SURGERY	TS	3				**3**
	FAMILY MEDICINE	FM	4				**4**
	PEDIATRICS	PED	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	2				**2**
	IMMUNOLOGY	IMM	2				**2**
	RADIOLOGY	RAD	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		**128**	3		2	**133**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				2x2=4 (4 Groups)	**4**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**128**	**3**	**6**	**6**	**143**
	INDEPENDENT LEARNING						**98**

Coordination Committee

HEAD	Ferda Özkan, MD, Prof.
SECRETARY	Banu Musaffa Salepçi, Assoc. Prof.
MEMBER	Müzeyyen Doğan, MD, Assoc. Prof.
MEMBER	Mustafa Aytek Şimşek, MD, Assist. Prof.
MEMBER	Emine Nur Özdamar, MD, Assist. Prof.

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS
LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Asst. Prof.
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
CHEST MEDICINE	Emine Sevda Özdoğan, MD, Prof. Banu Musaffa Salepçi, MD, Assoc. Prof.
CARDIOLOGY	Muzaffer Değertekin, MD, Prof. Olcay Özveren, MD, Assoc. Prof. Kartal Emre Aslanger MD, Assoc. Prof. AyçaTürer Cabbar, MD, Assist. Prof. Mustafa Aytek Şimşek, MD, Assist. Prof. Burak Hünük ,MD, Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. A. Çağrı Büke, MD, Prof
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD, Prof. Müzeyyen Doğan, MD, Assoc. Prof.
THORACIC SURGERY	Sina Ercan, MD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Prof.
PEDIATRICS	Hülya Sarıçoban, MD, Assoc. Prof. Fatma Tuba Coşkun, MD
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
RADIOLOGY	Ayşegül Görmez, MD.
EMERGENCY MEDICINE	Merve Ekşioğlu, MD. Mustafa Yazıcıoğlu, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Phd, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Sevda Özdoğan, MD, Prof. Ferdi Menda MD, Prof. Banu Musaffa Salepçi, MD, Assoc. Prof. Olcay Özveren, MD, Assoc. Prof. Ayça Türer Cabbar, MD, Assist. Prof. Mustafa Aytek Şimşek, MD, Assist. Prof. Nurcan Kızılcık, MD, Assist. Prof. Tuğhan Utku, MD, Assoc. Prof.

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. ***to convey*** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. ***to convey*** knowledge on principles of prescription,
8. ***to convey*** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. ***to convey*** necessary knowledge on radiation physics and biology and its use in oncology,
10. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. ***to convey*** knowledge on principles of biostatistical analysis,
12. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0.***recall*** anatomy, histology and physiology of cardiovascular and respiratory systems,

2.0.***explain*** etiopathogenesis of clinical conditions (*upper respiratory tract problems, nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement - pneumonia, tuberculosis, etc., circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insuffiency, tobacco use, lung tumors,other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

3.0.***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

4.0.***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,

5.0.***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

6.0.at multi-system level and/or related to cardiovascular and respiratory systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices

- which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (cardiovascular, pulmonary)

6.2. evaluation of emergency case (dyspnea)

6.3. approach to healthy individual or patient (cardiovascular disease, chest pain, cough and hemoptysis, dyspnea)

6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests)

6.5. imaging tests/examinations (radionuclide ventriculography, myocardial scintigraphy, cardiac PET, ventilation/perfusion scintigraphyi, PET in lung cancer)

6.6. point of care testing (urine strip/dipstick test)

6.7. making preliminary diagnosis or definitive diagnosis decision

6.8. making non-intervention or intervention decision

6.9. practicing non-intervention or intervention

6.10. referral/transport of healthy individual or patient

7.0.***define*** radiation physics, biology and its use in oncology,

8.0.***explain*** implementation of hypertension treatment guidelines,

9.0.***explain*** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, drugs used in the treatment of asthma and chronic obstructive pulmonary disease, antitussive, expectorant and surfactant drugs),

10.0 explain genetics of cardiovascular and respiratory system,

11.0.***explain*** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),

12.0.***explain*** principles of biostatistical analysis,

13.0.***perform*** basic clinical skills, practiced on phantom models (advanced cardiac life support), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition), required at primary health care service.

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
8.0.,9.0	PC	E. Genç E. N. Özdamar	17	8	8	33
1.0.,2.0	PT	F. Özkan A. Sav	17	7	7	31
1.0.,2.0.,5.0.,6.0-6.10	CHM	E. S. Özdoğan B. Salepçi	12	6	6	24
1.0.,2.0.,5.0.,6.0-6.10	CRD	M.Degertekin O. Özveren K. E Aslanger A. Cabbar B. Hünük M.A. Şimşek	11	4	4	19
3.0.,4.0	PH	R.E. Sezer H.A.Taşyıkan	6	2	2	10
2.0.,5.0	PP	M. Kaçar	5	2	2	9
2.0.,5.0.,6.0, 6,4	IDCM	M. Sönmezoğlu A.Ç. Büke	3	2	2	7
11.0	BED	E. Vatanoğlu Lutz	3	1	1	5
1.0.,2.0.,5.0.,6.0	ENT	M. Doğan Y. Selim Pata	3	1	1	5
12.0	BS	Ç. Altunok	2	1	1	4
6.3	TS	S. Ercan	2	1	1	4
1.0.,2.0.,5.0.,6.0, 6.10	FM	G.Izbırak Ö. Tanrıöver	2	1	1	4
2.0.,5.0, 6.3	PED	H. Sarıçoban T. Coşkun	2	1	1	4
10.0	MG	A.Ç. Kuşkucu	2	1	1	4
6.2	EM	M. Ekşioğlu M. Yazıcıoğlu	1	1	1	3
2.0.,5.0	IMM	G.Y. Demirel	1	1	1	3
6.5	RAD	A. Görmez	1	0	0	1
TOTAL			**90**	**40**	**40**	**170**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,5.0.,6.0-6.10	CHM	B. Salepçi	1	-	-	1
1.0.,2.0	PT	F. Özkan	2	-	-	2
8.0.,9.0	CRD	M. Değertekin	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****41** out of 200 FE and ICE MCQs will be from Committee II (Each question is of worth **0.5** pts).

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK I / 28 Oct - 1 Nov 2019

<table>
<tr><th></th><th>Monday
28-Oct-2019</th><th>Tuesday
29-Oct-2019</th><th>Wednesday
30-Oct-2019</th><th>Thursday
31-Oct-2019</th><th>Friday
1-Nov-2019</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">NATIONAL HOLIDAY</td><td>Lecture
General Signs and Principal Symptoms in Cardiovascular System Diseases
K. E. Aslanger</td><td colspan="4">ICP-CSL
(Advanced Cardiac Life Support)
F. Menda / N. Kızılcık / T. Utku</td><td>Coronary Artery Disease I
M. Değertekin</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Examination of the Heart
K. E. Aslanger</td><td rowspan="2">Group A
Small Group Study
SRPC</td><td rowspan="2">Group B ICP</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td>Lecture
Coronary Artery Disease II
M. Değertekin</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Hypertension
M. A. Şimşek</td><td>Lecture
Acetylcholinesterase Inhibitors
E. Genç</td></tr>
<tr><td>12.00- 12.50</td><td></td><td></td><td>Lecture
Pericardial Diseases
M. A. Şimşek</td><td colspan="4">Independent Learning</td><td>Lecture
Acetylcholine and Directly Acting Parasympathomimetic Drugs
E. Genç</td></tr>
<tr><td>12.50 - 14.00</td><td colspan="6">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">NATIONAL HOLIDAY</td><td>Lecture
Pathophysiology of Cardiovascular System Disorders I
M. Kaçar</td><td colspan="2">Lecture
Diuretic Agents I
E. N. Özdamar</td><td colspan="2">ICP-CSL
(Advanced Cardiac Life Support)
F. Menda / N. Kızılcık / T. Utku</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Pathophysiology of Cardiovascular System Disorders II
M. Kaçar</td><td colspan="2">Lecture
Diuretic Agents II
E. N. Özdamar</td><td rowspan="2">Group A
ICP</td><td rowspan="2">Group B
Small Group Study
SRPC</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Pathophysiology of Cardiovascular System Disorders III
M. Kaçar</td><td colspan="2">Lecture
Parasympatholitic Drugs
E. Genç</td></tr>
<tr><td>17.00-17.50</td><td>Lecture
Introduction to Autonomic System Pharmacology
E. Genç</td><td colspan="2">Lecture
Sympathomimetic Drugs: Catecholamines & Noncatecholamines
E. Genç</td><td colspan="4">Independent Learning</td></tr>
</table>

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK II / 4-8 Nov 2019

	Monday **4-Nov-2019**	**Tuesday** **5-Nov-2019**	**Wednesday** **6-Nov-2019**	**Thursday** **7-Nov-2019**	**Friday** **8-Nov-2019**
09.00- 09.50	**Lecture** Myocardium F. Özkan	**Lecture** Congestive Heart Failure I A. Türer Cabbar	**Lecture** Rheumatic Heart Disease A. Sav	**Independent Learning**	**Lecture** Pathophysiology of Respiratory System Disorders I M. Kaçar
10.00- 10.50	**Lecture** Ischemic Heart Disease I F. Özkan	**Lecture** Congestive Heart Failure II A. Türer Cabbar	**Lecture** CVS Tumors A. Sav		**Lecture** Pathophysiology of Respiratory System Disorders II M. Kaçar
11.00- 11.50	**Lecture** Ischemic Heart Disease II F. Özkan	**Lecture** Grown-up Congenital Heart Disease A. Türer Cabbar	**Lecture** Hypersensitivity reactions G. Yanıkkaya Demirel		**Lecture** Pathophysiology of Respiratory System Disorders III M. Kaçar
12.00- 12.50	**Lecture** Pharmacology of ReninAngiotensin System E. N. Özdamar	**Lecture** Pharmacology Case Studies E. Genç	**Lecture** Hypersensitivity reactions G. Yanıkkaya Demirel		**Lecture** Pathophysiology of Respiratory System Disorders IV M. Kaçar
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathology of Endocardium & Heart Valves I A. Sav	**Lecture** History and Symptoms in Pulmonary Diseases E. S. Özdoğan	**Lecture** Diagnostic Methods in Pulmonary Medicine S. Özdoğan	**Lecture** Electrocardiography I B. Hünük	**ICP-CSL** (Advanced Cardiac Life Support) F. Menda/ N. Kızılcık/ T. Utku
15.00- 15.50	**Lecture** Pathology of Endocardium & Heart Valves II A. Sav	**Lecture** Physical Examination and Signs in Pulmonary Diseases E. S. Özdoğan	**Lecture** Clinical Application of Pulmonary Function Tests S. Özdoğan	**Lecture** Electrocardiography II B. Hünük	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** SRPC
16.00- 16.50	**Lecture** Valvular Heart Diseases O. Özveren	**Lecture** Chronic Obstructive Pulmonary Disease E. S. Özdoğan	**Lecture** Bronchial Hyperreactivity and Asthma S. Özdoğan	**Lecture** Cardiac Arrhythmias B. Hünük	
17.00-17.50	**Lecture** Infective Endocarditis and Acute Rheumatic Fever O. Özveren	**Lecture** Adrenergic Receptor Blockers E. Genç	**Lecture** Congenital Heart Disease in Pediatrics T. Çoşkun	**Lecture** Adrenergic Neuron Blockers E. Genç	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK III / 11-15 Nov 2019

	Monday 11-Nov-2019	Tuesday 12-Nov-2019	Wednesday 13-Nov-2019	Thursday 14-Nov-2019	Friday 15-Nov-2019
09.00- 09.50	**Lecture** Diseases of the Nose and Paranasal Sinuses Y. S. Pata	**Lecture** Pulmonary Tuberculosis S. Özdoğan	**Lecture** Pulmonary Infections I F. Özkan	**Independent Learning**	**Lecture** Ethical Issues at the Beginning of Life E. Vatanoğlu Lutz
10.00- 10.50	**Lecture** Nasopharyngeal and Oropharyngeal Diseases Y. S. Pata	**Lecture** Pulmonary Embolism S. Özdoğan	**Lecture** Pulmonary Infections II F. Özkan		**Lecture** Ethical Issues in Paediatrics E. Vatanoğlu Lutz
11.00- 11.50	**Lecture** Atherosclerosis & Hypertension I A. Sav	**Lecture** Special Pulmonary Problems S. Özdoğan	**Lecture** Tracheobronchitis B. Salepçi		**Lecture** Ethics in Intensive Care E. Vatanoğlu Lutz
12.00- 12.50	**Lecture** Atherosclerosis & Hypertension II A. Sav	**Lecture** Emergency Evaluation of Dyspnea M. Ekşioğlu	**Lecture** Pneumoniae B. Salepçi		**Lecture** Ethics in Psychiatry E. Vatanoğlu Lutz
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Principals of Statistical Analysis I Ç. Altunok	**Lecture** Laryngeal and Voice Diseases M. Doğan	**Independent Learning**	**Lecture** Pulmonary Hypertension B. Salepçi	**ICP-CSL** (Advanced Cardiac Life Support) F. Menda / N. Kızılcık / T. Utku
15.00- 15.50	**Lecture** Principals of Statistical Analysis II Ç. Altunok	**Lecture** Diseases of the Middle Ear and Eustachian Tube M. Doğan		**Lecture** Respiratory Failure B. Salepçi	**Group A IL** | **Group B IL** | **Group C** **Small Group Study** SRPC | **Group D** **ICP**
16.00- 16.50	**Lecture** Drugs Used in the Treatment of Dyslipidemias I E. N. Özdamar	**Lecture** Drugs Used in Cardiac Arrythmias I E. N. Özdamar		**Lecture** Inherited Respiratory System Disorders A. Kuşkucu	
17.00-17.50	**Lecture** Drugs Used in the Treatment of Dyslipidemias II E. N. Özdamar	**Lecture** Drugs Used in Cardiac Arrythmias II E. N. Özdamar		**Lecture** Inherited Cardiovascular Disorders A.Ç. Kuşkucu	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK IV / 18-22 Nov 2019

	Monday 18-Nov-2019	Tuesday 19-Nov-2019	Wednesday 20-Nov-2019	Thursday 21-Nov-2019	Friday 22-Nov-2019
09.00- 09.50	**Independent Learning**	**Lecture** Chronic Obstructive Pulmonary Diseases F. Özkan	**Lecture** Tumors of the Respiratory System I A. Sav	**Independent Learning**	**Independent Learning**
10.00- 10.50		**Lecture** Asthma Bronchiale F. Özkan	**Lecture** Tumors of the Respiratory System II A. Sav	**Lecture** Drugs Used in the Treatment of Angina Pectoris E. N. Özdamar	
11.00- 11.50		**Lecture** Congenital Lung Anomalies & Atalectasis F. Özkan	**Lecture** Congestive Heart Failure F. Özkan	**Lecture** Hypertension Treatment Guidelines E. N. Özdamar	
12.00- 12.50		**Lecture** Pathology of Upper Respiratory Tract F. Özkan	**Lecture** Congestive Heart Failure & Pericardium F. Özkan	**Lecture** Anticoagulant, Antiplatelet & Thrombolytic drugs E. N. Özdamar	
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Özdoğan	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Özdoğan	**Lecture** Anti-hypertensive Drugs I E. N. Özdamar	**Lecture** Pathology of Pleural and Mediastinal Diseases A. Sav	**Pathology Laboratory** (Cardiovascular and Respiratory Systems) F. Özkan / A. Sav **Group B** / **Group A IL**
15.00- 15.50	**Group C** **ICP** / **Group D** **Small Group Study** SRPC / **Group A IL** / **Group B IL**	**Group C** **Small Group Study** SRPC / **Group D** **ICP** / **Group A IL** / **Group B IL**	**Lecture** Anti-hypertensive Drugs II E. N. Özdamar	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases I R.E. Sezer	
16.00- 16.50			**Lecture** Pediatric Advanced Life Support M. Yazıcıoğlu	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases II R.E. Sezer	**Group B IL** / **Group A**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases III R.E. Sezer	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK V / 25-29 Nov 2019

	Monday 25-Nov-2019	Tuesday 26-Nov-2019	Wednesday 27-Nov-2019	Thursday 28-Nov-2019	Friday 29-Nov-2019
09.00- 09.50	**Lecture** Preparing to Analyse Data Ç. Altunok	**Lecture** Bloodstream Invasion & Sepsis I M. Sönmezoğlu	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Özdoğan	**Independent Learning**	**Lecture** Chronic Restrictive Pulmonary Diseases I A. Sav
10.00- 10.50	**Lecture** Respiratory Muscles and Surgical Anatomy of Thorax S. Ercan	**Lecture** Bloodstream Invasion & Sepsis II M. Sönmezoğlu	**Group C IL** / **Group D IL** / **Group B ICP** / **Group A Small Group Study** SRPC		Chronic Restrictive Pulmonary Diseases II A. Sav
11.00- 11.50	**Lecture** Surgical Disorders of Mediastinum and the Diaphragm S. Ercan	**Lecture** Cardiac Infections M. Sönmezoğlu			**Lecture** Congenital Heart Disease I A. Sav
12.00- 12.50	**Lecture** Surgical Treatment of Pulmonary Diseases S. Ercan	**Lecture** Treatment of Cough & Drugs Used in the Treatment of Common Cold E. N. Özdamar	**Independent Learning**		**Lecture** Congenital Heart Disease II A. Sav
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to Radiation Oncology H. Aydın	**Lecture** Approach to the Patient with Cough and Heameoptysis in Primary Care Ö. Tanrıöver	**Lecture** Pharmacology and Toxicology of Tobacco E. N. Özdamar	**Independent Learning**	**ICP-CSL** (Examination of Cardiovascular and Respiratory System) O. Özveren / M. A. Şimşek / B. Salepçi / S. Özdoğan
15.00- 15.50	**Lecture** Basics of Radiation Biology and Radiation Physics H. Aydın	**Lecture** Approach to the Patient with Dyspnea in Primary Care Ö. Tanrıöver	**Lecture** Drugs Used in the Treatment of Asthma & Chronic Obstructive Lung Disease E. N. Özdamar		**Group C IL** / **Group D IL** / **Group B Small Group Study** SRPC / **Group A ICP**
16.00- 16.50	**Independent Learning**	**Lecture** Drugs Used in Congestive Heart Disease I E. N. Özdamar	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases IV R.E. Sezer		
17.00-17.50		**Lecture** Drugs Used in Congestive Heart Disease II E. N. Özdamar	**Lecture** Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases R.E. Sezer		**Independent Learning**

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK VI / 2-6 Dec 2019

	Monday 2-Dec-2019	Tuesday 3-Dec-2019	Wednesday 4-Dec-2019	Thursday 5-Dec-2019	Friday 6-Dec-2019
09.00- 09.50	**Lecture** Bronchiectasis B. Salepçi	**Lecture** Upper and Lower Respiratory System Infections I A.Ç. Büke	**Lecture** Interstitial Lung Diseases B. Salepçi	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Lung Cancer B. Salepçi	**Lecture** Upper and Lower Respiratory System Infections II A.Ç. Büke	**Lecture** Sleep Apnea Syndrome B. Salepçi		
11.00- 11.50	**Lecture** Pleural Diseases B. Salepçi	**Lecture** Approach to Patient with Chest Pain in Primary Care I G. İzbırak	**Multidisciplinary Case Discussion Panel**		
12.00- 12.50	**Lecture** X-Ray Examination of the Lungs A. Görmez	**Lecture** Approach to Patient with Chest Pain in Primary Care II G. İzbırak	**Multidisciplinary Case Discussion Panel**		
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Approach to the Pediatric Patient with Pneumonia H. Sarıçoban	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**
15.00- 15.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases I H.A.Taşyıkan				
16.00- 16.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases II H.A.Taşyıkan				
17.00-17.50	**Lecture** Public Health and Chronic Non-Communicable Diseases H.A. Taşyıkan				

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
WEEK VII / 9-13 Dec 2019

	Monday 9-Dec-2019	Tuesday 10-Dec-2019	Wednesday 11-Dec-2019	Thursday 12-Dec-2019	Friday 13-Dec-2019
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
13.00- 14.00	LUNCH BREAK				Program Evaluation Session Committee II Coordination Committee Members
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

COMMITTEE III - GASTROINTESTINAL SYSTEM

DISTRIBUTION of LECTURE HOURS

December 16, 2019 - January 10, 2020

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	GASTROENTEROHEPATOLOGY	GE	24				**24**
	PATHOLOGY	PT	14		1x3=3 (2 Groups)		**17**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	10				**10**
	PHARMACOLOGY	PC	5				**5**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	4				**4**
	PUBLIC HEALTH	PH	3				**3**
	PHYTOTHERAPY	PHY	3				**3**
	BIOSTATISTICS	BS	3				**3**
	IMMUNOLOGY	IMM	2				**2**
	PATHOPHYSIOLOGY	PP	2				**2**
	FAMILY MEDICINE	FM	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	2				**2**
	RADIOLOGY	RAD	1				**1**
	PEDIATRICS	PED	1				**1**
	PEDIATRIC SURGERY	PEDS	1				**1**
	GENERAL SURGERY	GS	1				**1**
	INTERDISCIPLINARY	MCDP				2	2
	TOTAL		80		3	2	85
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				1X2=2 (4 Groups)	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			1X3=3 (4 Groups)		**3**
TOTAL			**80**		**6**	**4**	**90**
	INDEPENDENT LEARNING						**45**

Coordination Committee

HEAD	Meltem Ergün, MD, Assoc. Prof.
SECRETARY	Barış Murat Ayvacı, MD, Assist. Prof.
MEMBER	Ferda Özkan, MD, Prof.
MEMBER	Şafak Karaçay, MD, Assoc. Prof.
MEMBER	Emine Nur Özdamar, MD, Assist. Prof.

COMMITTEE III - GASTROINTESTINAL SYSTEM
LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
GASTROENTEROHEPATOLOGY	Cengiz Pata, MD, Prof. Meltem Ergün, MD, Assoc. Prof.
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu Lutz, MD, Assoc. Prof.
INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. A. Çağrı Büke, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof. M. Engin Celep, PhD, Assist. Prof
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc. Prof. Barış Murat Ayvacı, MD, Assist. Prof.
PEDIATRICS	Meltem Uğraş, MD, Prof.
PEDIATRIC SURGERY	Şafak Karaçay, MD, Assoc.Prof.
GENERAL SURGERY	Gürkan Tellioğlu, MD, Prof.
RADIOLOGY	Serpil Kurtcan, MD
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Dilek Barutçu Ataş, MD, Assist. Prof. Güldal İzbırak, MD, Assoc. Prof. Serdar Özdemir, MD, Assist. Prof. Fatih Ağalar, MD, Prof. Mirkhalig Javadov, MD, Assist. Prof.

COMMITTEE III - GASTROINTESTINAL SYSTEM
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. ***to convey*** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. ***to convey*** knowledge on biostatistical analysis of association between variables,
10. ***to convey*** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. ***to equip with*** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.
12. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of gastrointestinal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,

5.0. ***explain*** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,

6.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

7.0. at multi-system level and/or related to gastrointestinal system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

7.1. practice of history taking and physical examination (gastrointestinal)
7.2. evaluation of emergency case (acute abdominal pain)
7.3. approach to healthy individual or patient (diarrhea)
7.4. laboratory tests/examinations
7.5. imaging tests/examinations (scintigraphy of liver/spleen, PET in gastrointestinal system tumors)
7.6. point of care testing
7.7. making preliminary diagnosis or definitive diagnosis decision
7.8. making non-intervention or intervention decision
7.9. practicing non-intervention or intervention
7.10. referral/transport of healthy individual or patient

8.0. ***list*** differences of gastrointestinal clinical conditions that may occur in children,

9.0. ***explain*** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),

10.0. ***explain*** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, laxatives) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,

11.0. ***explain*** genetics of gastrointestinal system,

12.0. ***explain*** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,

13.0. ***define*** biostatistical analysis of association between variables,

14.0. ***tell*** legal regulations and ethical principles for end-of-life decisions,

15.0. ***perform*** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition), required at primary health care service.

16.0. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy.

COMMITTEE III - GASTROINTESTINAL SYSTEM
COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE III - GASTROINTESTINAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0-7.10	GE	C. Pata M. Ergün	27	7	7	**41**
2.0.,6.0.,7.4	PT	F. Özkan	17	4	4	**25**
14.0	BED	E. Vatanoğlu	11	3	3	**17**
10.0	PC	E. Genç E. N. Özdamar	6	2	2	**10**
2.0.,3.0.,4.0.,6.0.,7.0, 7.4	IDCM	M. Sönmezoğlu A.Ç. Büke	6	1	1	**8**
3.0.,4.0.,5.0	PH	R.E. Sezer H.A.Taşyıkan	3	1	1	**5**
12.0, 16.0	PHR (PHY)	E. Yeşilada	3	1	1	**5**
13.0	BS	Ç. Altunok	3	1	1	**5**
2.0.,6.0	IMM	G. Y. Demirel	2	1	1	**4**
2.0.,6.0	PP	M. Kaçar	2	1	1	**4**
7.2, 7.3, 7.10	FM	G. İzbırak Ö. Tanrıöver	2	1	1	**4**
11.0	MG	A.Ç. Kuşkucu	2	1	1	**4**
2.0.,3.0.,4.0.,6.0.,7.2	EM	S. Sarıkaya B. M. Ayvacı	2	0	0	**2**
7.5	RAD	S. Kurtcan	1	0	0	**1**
5.0, 8.0	PED	M. Uğraş	1	0	0	**1**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0	PEDS	Ş. Karaçay	1	0	0	**1**
9.0	GS	G. Tellioğlu	1	0	0	**1**
		TOTAL	**90**	**24**	**24**	**138**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0	GE	M. Ergün	3	-	-	3
2.0.,6.0.,7.4	PT	F. Özkan	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:** Points
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****23** out of 200 FE and ICE MCQs will be from Committee III (Each question is of worth **0.5** pts).

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK I / 16-20 Dec 2019

	Monday 16-Dec-2019	Tuesday 17-Dec-2019	Wednesday 18-Dec-2019	Thursday 19-Dec-2019	Friday 20-Dec-2019
09.00- 09.50	**Lecture** Palliative Care Ethics E. Vatanoğlu Lutz	**Lecture** Ethics of Dealing with Addiction E. Vatanoğlu Lutz	**Lecture** Abdominal Pain M. Ergün	**Lecture** Complex Diseases-Inherited Gastrointestinal System Disorders A.Ç. Kuşkucu	**Lecture** Functional GI Disorders & Irritable Bowel Disease C. Pata
10.00- 10.50	**Lecture** Medical Ethical Decision-Making E. Vatanoğlu Lutz	**Lecture** Ethics of Elective Interventions E. Vatanoğlu Lutz	**Lecture** Disease of the Bile Duct and Gall Bladder M. Ergün	**Lecture** Complex Diseases-Inherited Gastrointestinal System Disorders A.Ç. Kuşkucu	**Lecture** Acute Gastroenteritis M. Sönmezoğlu
11.00- 11.50	**Lecture** Ethics and the Law E. Vatanoğlu Lutz	**Lecture** The Ethics of Testing and Screening E. Vatanoğlu Lutz	**Lecture** Steatohepatitis M. Ergün	**Lecture** Radiology of Gastrointestinal System S. Kurtcan	**Lecture** Hepatitis I M. Sönmezoğlu
12.00- 12.50	**Lecture** Public Health Ethics E. Vatanoğlu Lutz	**Lecture** The Ethics of Dealing with Infectious Diseases E. Vatanoğlu Lutz	**Lecture** Acute Liver Failure M. Ergün	**Lecture** Approach to the Patient with Abdominal Pain Regarding to Primary Care G. İzbırak	**Lecture** Hepatitis II M. Sönmezoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** The Ethics of Patents on Life E. Vatanoğlu Lutz	**Lecture** Ethical Issues at the End of Life E. Vatanoğlu Lutz	**Lecture** Wilson Disease and Hemochromatisis M. Ergün	**Lecture** Malabsorbtion C. Pata	**ICP-CSL** (History Taking and Physical Examination of Gastrointestinal System) F. Ağalar / M. Javadov / S. Özdemir / G.İzbırak
15.00- 15.50	**Lecture** Pathophysiology of Gastro–intestinal Disorders I M. Kaçar	**Lecture** Laxatives E. N. Özdamar	**Lecture** Acute and Chronic Pancreatitis M. Ergün	**Lecture** Inflammatory Bowel Disease C. Pata	**Group D** **Small Group Study** SRPC **Group C** **ICP** **Group A** **IL** **Group B** **IL**
16.00- 16.50	**Lecture** Pathophysiology of Gastro–intestinal Disorders II M. Kaçar	**Lecture** Immunologic Tolerance and Autoimmunity G. Yanıkkaya Demirel	**Lecture** Tumors of the Bile Ducts and Pancreas M. Ergün	**Lecture** Food Poisoning A.Ç. Büke	
17.00-17.50	**Lecture** Clinical Approach to the Patient with Acute Abdominal Pain S. Sarıkaya	**Lecture** Immunologic Tolerance and Autoimmunity G. Yanıkkaya Demirel	**Lecture** Gastrointestinal Bleedings in Children Ş. Karaçay	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK II / 23-27 Dec 2019

	Monday 23-Dec-2019	Tuesday 24-Dec-2019	Wednesday 25-Dec-2019	Thursday 26-Dec-2019	Friday 27-Dec-2019
09.00- 09.50	**Lecture** Public Health and Nutrition I R.E. Sezer	**Lecture** Oral Pathology F. Özkan	**Lecture** Gastritis and Helicobacter Pylori C. Pata	**Lecture** Pathology of Stomach I F. Özkan	**Lecture** Clinical Nutrition M. Uğraş
10.00- 10.50	**Lecture** Public Health and Nutrition II R.E. Sezer	**Lecture** Pathology of Esophagus I F. Özkan	**Lecture** Gastroeusophegeal Reflux (GE) and Esophageal Motility Disorder C. Pata	**Lecture** Pathology of Stomach II F. Özkan	**Lecture** Transplantation of liver G. Tellioğlu
11.00- 11.50	**Lecture** Semiology I C. Pata	**Lecture** Pathology of Esophagus II F. Özkan	**Lecture** Tumors of Eusophagus, Stomach and Small Intestine C. Pata	**Lecture** Agents used in the Treatment of Peptic Ulcer I E. Genç	**Lecture** Pathology of Liver I F. Özkan
12.00- 12.50	**Lecture** Semiology II C. Pata	**Lecture** Comparing Groups-categorical Data Ç. Altunok	**Lecture** Cirrhosis and Portal Hypertension M. Ergün	**Lecture** Agents used in the Treatment of Peptic Ulcer II E. Genç	**Lecture** Pathology of Liver II F. Özkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Peptic Ulcer Disease C. Pata	**Lecture** Comparing Groups-countinous Data I Ç. Altunok	**Lecture** Phytotherapy-IV E. Yeşilada	**Lecture** Premalignant Lesion of the Colon M. Ergün	**ICP-CSL** (History Taking and Physical Examination of Gastrointestinal System) F. Ağalar / M. Javadov / / S. Özdemir / G. İzbırak
15.00- 15.50	**Lecture** Autoimmune Hepatitis C. Pata	**Lecture** Comparing Groups-countinous Data II Ç. Altunok	**Lecture** Phytotherapy-V E. Yeşilada	**Lecture** Alcoholic Liver Disease M. Ergün	**Group C IL** / **Group D IL** / **Group A** Small Group Study SRPC / **Group B**
16.00- 16.50	**Lecture** Approach to the Patient with Diarrhea Regarding to Primary Care Ö. Tanrıöver	**Lecture** Epidemiology, Prevention and Control of Obesity H. A. Taşyıkan	**Lecture** Phytotherapy-VI E. Yeşilada	**Introduction to Elective Course (Fine Arts Building Conference Hall)**	
17.00-17.50	**Lecture** Mesenteric Ischemia B. M. Ayvacı	**Lecture** Pathophysiology of Gastrointestinal Disorders III M. Kaçar	**Lecture** Pathology of Appendix & Peritoneum F. Özkan	**Introduction to Elective Course (Fine Arts Building Conference Hall)**	**Independent Learning**

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK III / 30 Dec 2019 – 3 Jan 2020

	Monday 30-Dec-2019	Tuesday 31-Dec-2019	Wednesday 1-Jan-2020	Thursday 2-Jan-2020	Friday 3-Jan-2020
09.00- 09.50	**Lecture** Pathology of Liver & Biliary System I F. Özkan	**Lecture** Antiemetic Agents E. N. Özdamar	**New Year's Day**	**Lecture** Pathology of Intestinal Diseases I F. Özkan	**Independent learning**
10.00- 10.50	**Lecture** Pathology of Liver & Biliary System II F. Özkan	**Lecture** Digestive & Antidiarrheal Drugs E. N. Özdamar		**Lectureo** Pathology of Intestinal Diseases II F. Özkan	
11.00- 11.50	**Lecture** Pathology of Liver & Biliary System III F. Özkan	**Lecture** Jaundice C. Pata		**Lecture** Toxic Hepatitis M. Ergün	
12.00- 12.50	**Lecture** Pathology of Liver & Biliary System IV F. Özkan	**Lecture** Chronic Viral Hepatitis C. Pata		**Lecture** Mass Lesions of the Liver M. Ergün	
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Pathology Laboratory** (Gastrointestinal System) F. Özkan/ A. Sav **Group B** / **Group A IL**	**Multidisciplinary Case Discussion Panel**	**New Year's Day**	**ICP-CSL** (History Taking and Physical Examination of Gastrointestinal System) F. Ağalar / M. Javadov / S. Özdemir / G. İzbırak	**ICP-CSL** (History Taking and Physical Examination of Gastrointestinal System) F. Ağalar / M. Javadov / S. Özdemir / G. İzbırak
15.00- 15.50		**Multidisciplinary Case Discussion Panel**		**Group A ICP** / **Group B Small Group Study** SRPC / **Group C IL** / **Group D IL**	**Group A IL** / **Group B IL** / **Group D ICP** / **Group C Small Group Study** SRPC
16.00- 16.50	**Group B IL** / **Group A**	**Independent learning**			
17.00-17.50	**Independent learning**	**Independent learning**		**Independent Learning**	**Independent Learning**

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK IV / 6 - 10 Jan 2020

	Monday 6-Jan-2020	Tuesday 7-Jan-2020	Wednesday 8-Jan-2020	Thursday 9-Jan-2020	Friday 10-Jan-2020
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				Program Evaluation Session Committee III Coordination Committee Members
14.00- 14.50	Independent learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
15.00 -15.50					
16.00 - 16.50					
17.00 - 17.50					

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

DISTRIBUTION of LECTURE HOURS

January 13, 2020 – March 20, 2020

COMMITTEE DURATION: 8 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PATHOLOGY	PT	32		1x2=2 (2 Groups)		**34**
	OBST & GYNEC	OBS-GYN	16				**16**
	ENDOCRINOLOGY	END	15				**15**
	NEPHROLOGY	NE	15				**15**
	PHARMACOLOGY	PC	14				**14**
	INFECTIOUS DISEASES	ID	5				**5**
	MEDICAL MICROBIOLOGY	MM	0		2x1=2 (4 Groups)		**2**
	PATHOPHYSIOLOGY	PP	7				**7**
	MEDICAL GENETICS	MG	6				**6**
	PEDIATRICS	PED	6				**6**
	UROLOGY	URO	6				**6**
	FAMILY MEDICINE	FM	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	BIOSTATISTICS	BS	3				**3**
	IMMUNOLOGY	IM	2				**2**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	2				**2**
	PHYTOTHERAPY	PHR	2				**2**
	RADIOLOGY	RAD	2				**2**
	EMERGENCY MEDICINE	EM	1				**1**
	PEDIATRIC SURGERY	PED-S	1				**1**
	HISTOLOGY	HST	1				**1**
	GENERAL SURGERY	GS	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		145		4	2	**151**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				2x2=4 (4 Groups)	**4**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			1x3=3 (4 Groups) 1x2=2 (4 Groups) 1x3=3 (4 Groups)		**8**
TOTAL			**145**		**12**	**6**	**163**
	INDEPENDENT LEARNING						**101**

Coordination Committee

HEAD	Hasan Aydın, MD, Prof.
SECRETARY	Oya Alagöz, MD, Assist. Prof.
MEMBER	Gülçin Kantarcı, MD, Prof.
MEMBER	Rukset Attar, MD, Prof.
MEMBER	Erdem Söztutar, MD, Assist. Prof.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
OBSTETRICS and GYNECOLOGY	Orhan Ünal, MD, Prof. Selçuk Özden, MD, Prof. Rukset Attar, MD, Prof. Gazi Yıldırım, MD, Prof.
ENDOCRINOLOGY	Hasan Aydın, MD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
INFECTIOUS DISEASES	Meral Sönmezoğlu, MD Prof. A.Çağrı Büke, MD, Prof.
MEDICAL MICROBIOLOGY	İ. Çağatay Acuner, MD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu Lutz, MD, PhD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Assist. Prof.
FAMILY MEDICINE	Özlem Tanrıöver, MD, Prof. Ayşe Arzu Akalın, MD, Assist. Prof.
PEDIATRICS	Mustafa Berber, MD, Assist. Prof. Fatma Tuba Coşkun, MD Belma Haliloğlu, MD, Assoc. Prof. Çiğdem Ayanoğlu, MD.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
RADIOLOGY	Özgür Sarıca, MD.
PHYTOTHERAPY	Erdem Yeşilada, MD, Prof. M. Engin Celep, PhD, Assist. Prof.
HISTOLOGY & EMBRYOLOGY	Oya Alagöz, MD, Assist. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD, Prof. Dilek Barutçu Ataş, MD, Assist. Prof.
UROLOGY	Faruk Yencilek, MD, Prof. Murat Kuru, MD.
PEDIATRIC SURGERY	Şafak Karaçay, MD, Assoc. Prof.
GENERAL SURGERY	Gürkan Tellioğlu, MD, Prof.
EMERGENCY MEDICINE	Emin Gökhan Gencer, MD, Assist. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Filiz Bakar, MD, Prof. Rukset Attar, MD, Prof. Gazi Yıldırım, MD, Prof. Özlem Tanrıöver, MD, Prof. Ayşe Arzu Akalın, MD, Assist. Prof. Mustafa Berber, MD, Assist. Prof. Çiğdem Yanar Ayanoğlu, MD

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS
AIMS and LEARNING OBJECTIVES

ENDOCRINE & REPRODUCTIVE SYSTEMS

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. ***to convey*** knowledge on health care service practices related to reproductive care,
3. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. ***to convey*** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. ***to convey*** knowledge on genetics of endocrine and reproductive systems,
10. ***to convey*** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. ***to convey*** knowledge on design and biostatistical analysis of survival research,
12. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
13. ***to equip with*** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2.0. ***explain*** physiology of normal spontaneous vaginal delivery,
3.0. ***define*** practice of reproductive care,
4.0. ***explain*** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,

7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

8.0. at multi-system level and/or related to endocrine and reproductive systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (gynecological, breast)

8.2. evaluation of emergency case

8.3. approach to healthy individual or patient (pregnancy)

8.4. laboratory tests/examinations (venous blood collection, throat swab specimen, sputum sample collection, thyroid function tests, diabetes tests, rapid screening [antigen/antibody] tests, throat culture, sputum culture)

8.5. imaging tests/examinations (radiological examinations in gynecology, breast imaging, radioisotope imaging of thyroid and parathyroid)

8.6. point of care testing (diabetes tests, rapid screening [antigen/antibody] tests)

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0. ***explain*** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,

10.0. ***explain*** genetics of endocrine and reproductive systems,

11.0. ***explain*** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,

12.0. ***define*** design and biostatistical analysis of survival research,

13.0. ***explain*** legal regulations and ethical principles related to reproductive care,

14.0. ***perform*** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

URINARY SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of urinary system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. ***to convey*** knowledge on genetics of urinary system,
9. ***to convey*** knowledge on phytotherapeutic agenst that are effective on urinary system or on clinical conditions involving urinary system,
10. ***to convey*** knowledge on use of biostatistical software and presentation of results,
11. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
12. ***to equip with*** basic and advanced clinical skills *(gynecological examination, "Pap-smear" collection, intrauterine device placement, breast examination, physical examination in neonate, infant and prepubertal/pubertal child)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

U1.0. ***recall*** anatomy, histology and physiology of urinary system,

U2.0. ***explain*** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

U3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

U4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,

U5.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

U6.0. at multi-system level and/or related to urinary system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

U6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal)
U6.2. evaluation of emergency case (urological emergencies)
U6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen, fecal specimen collection)
U6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture, fecal culture)
U6.5. imaging tests/examinations (uroradiology, renal scintigraphy (GFR, ERPF, Renogram))
U6.6. point of care testing
U6.7. making preliminary diagnosis or definitive diagnosis decision
U6.8. making non-intervention or intervention decision
U6.9. practicing non-intervention or intervention
U6.10. referral/transport of healthy individual or patient
U7.0. ***explain*** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
U8.0. ***explain*** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,
U9.0. ***explain*** genetics of urinary system,
U10.0. ***explain*** mechanisms of action for action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,
U11.0. ***define*** use of biostatistical software and presentation of results,
U12.0. ***perform*** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination, “Pap-smear” collection, intrauterine device placement, breast examination, physical examination in neonate, infant and prepubertal/pubertal child), required at primary health care service.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MED 302 INTRODUCTION to CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0, 4.0, 7.0, 8.4, U1, U2, U6.4	PT	F. Özkan A. Sav	20	10	10	**40**
1.0-8.10	OBS-GYN	S. Özden R. Attar G. Yıldırım	10	5	5	**20**
1.0, 4 - 8.10	END	H. Aydın	9	5	5	**19**
U1.0 - U6.0	NE	G. Kantarcı D. B. Ataş	9	5	5	**19**
9.0 , U7.0, U8.0	PC	E. Genç E. N. Özdamar	9	4	4	**17**
4.0 - 8.0, 8.4, U5, U6.0, U6.4	IDCM	M. Sönmezoğlu A. Ç. Büke	3	2	2	**7**
4.0, 7.0, U2.0, U5.0	PP	M. Kaçar	4	2	2	**8**
10.0, U9.0	MG	A. Ç. Kuşkucu	4	2	2	**8**
1.0, 4.0-8.0, U6.1	PED	Ç. Ayanoğlu B. Haliloğlu M. Berber T. Coşkun	4	2	2	**8**
U1.0.-U6.10	URO	F. Yencilek	4	2	2	**8**
6.0, 8.0,8.1, 8.3, 8.10, U2.0	FM	A. Akalın Ö. Tanrıöver	2	2	2	**6**
5.0, 6.0, U3.0, U4.0	PH	R.E. Sezer H.A. Taşyıkan	2	1	1	**4**
12.0, U11.0	BS	Ç. Altunok	2	1	1	**4**
4.0, 7.0, U2.0, U5.0	IMM	G. Y. Demirel	1	1	1	**3**
13.0	BED	E. Vatanoğlu Lutz	1	1	1	**3**
11.0	PHR (PHY)	E. Yeşilada	1	1	1	**3**
8.5, U6.5	RAD	Ö. Sarıca	1	1	1	**3**
7.0, U6.2	EM	E. G. Gencer	1	0	0	**1**
1.0.-6.0	PED-S	Ş. Karaçay	1	0	0	**1**
1.0	HST	O. Akçin	1	0	0	**1**
1.0.-6.0	GS	G. Tellioğlu	1	0	0	**1**
		TOTAL	**90**	**47**	**47**	**184**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER of QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 4 - 8.10	END	H. Aydın	1	-	-	**1**
1.0-8.10	OBS-GYN	R. Attar	1	-	-	**1**
U1.0 - U6.0	NE	G. Kantarcı	1	-	-	**1**
U1.0.-U6.10	URO	F. Yencilek	1	-	-	**1**
1.0, 4.0, 7.0, 8.4, U1, U2, U6.4	PT	F. Özkan	1	-	-	**1**
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****45** out of 200 FE and ICE MCQs will be from Committee IV (Each question is of worth **0.5** pts).

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEM
WEEK I / 13 – 17 Jan 2020

	Monday 13-Jan-2020	Tuesday 14-Jan-2020	Wednesday 15-Jan-2020	Thursday 16-Jan-2020	Friday 17-Jan-2020			
09.00- 09.50	**Lecture** Introduction to Endocrinology H. Aydın	**Lecture** Pathology of Adrenal Gland I A. Sav	**Lecture** Pathophysiology of Endocrine System Diseases I M. Kaçar	**Independent Learning**	**Lecture** Introduction to Endocrine Pharmacology E. Genç			
10.00- 10.50	**Lecture** Introduction to Diabetes Mellitus H. Aydın	**Lecture** Pathology of Adrenal Gland II A. Sav	**Lecture** Pathophysiology of Endocrine System Diseases II M. Kaçar		**Lecture** Thyroid and Antithyroid Drugs I E. Genç			
11.00- 11.50	**Lecture** Clinical and Laboratory Findings of Diabetes Mellitus H. Aydın	**Lecture** Pathology of Thyroid & Parathyroid I A. Sav	**Lecture** Pathophysiology of Endocrine System Diseases III M. Kaçar		**Lecture** Thyroid and Antithyroid Drugs II E. Genç			
12.00- 12.50	**Lecture** Obesity H. Aydın	**Lecture** Pathology of Thyroid & Parathyroid II A. Sav	**Lecture** Hypertensive Disorders in Pregnancy E.G. Gencer		**Lecture** Imaging of Thyroid Glands Ö. Sarıca			
12.50 – 14.00	**LUNCH BREAK**							
14.00- 14.50	**Lecture** Pathology of Endocrine System: Introduction A. Sav	**Lecture** Calcium Metabolism H. Aydın	**Lecture** Prenatal Genetic Diagnosis A. Ç. Kuşkucu	**Lecture** Hypocalcemic Diseases H. Aydın	**ICP-CSL** (Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining) R. Attar / G. Yıldırım		**ICP-CSL** (Physical Examination of the Newborn and Child Patient) Ç. Ayanoğlu/ M. Berber	
15.00- 15.50	**Lecture** Pathology of Pituitary Gland I A. Sav	**Lecture** Physical Examination of Newborn Patient M. Berber	**Lecture** Genetic Counseling A. Ç. Kuşkucu	**Lecture** Adrenal Disorders H. Aydın	**Group A ICP**	**Group B Small Group Study** SRPC	**Group C ICP-CSL**	**Group D IL**
16.00- 16.50	**Lecture** Pathology of Pituitary Gland II A. Sav	**Lecture** Physical Examination of Child Patient M. Berber	**Independent Learning**	**Lecture** Hypoglycemia H. Aydın				
17.00-17.50	**Lecture** Congenital Adrenal Hyperplasia B. Haliloğlu	**Independent Learning**	**Independent Learning**	**Lecture** Hypercalcemic Diseases H. Aydın	**Independent Learning**			

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

MIDTERM BREAK

20 JANUARY – 02 FEBRUARY 2020

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK II / 3 – 7 Feb 2020

<table>
<tr><th></th><th>Monday
3-Feb-2020</th><th>Tuesday
4-Feb-2020</th><th>Wednesday
5-Feb-2020</th><th>Thursday
6-Feb-2020</th><th colspan="4">Friday
7-Feb-2020</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Relation Between Two Variables I
Ç. Altunok</td><td>Lecture
Reproductive Ethics
E. Vatanoğlu Lutz</td><td>Lecture
Genetic Disorders of Gonadal Development
A. Ç. Kuşkucu</td><td rowspan="4">Independent Learning</td><td colspan="2">ICP-CSL
(Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining)
R. Attar / G. Yıldırım</td><td colspan="2">ICP-CSL
(Physical Examination of the Newborn and Child Patient)
Ç.Ayanoğlu/ M. Berber</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Relation Between Two Variables II
Ç. Altunok</td><td>Lecture
Gene Ethics
E. Vatanoğlu Lutz</td><td>Lecture
Genetic Disorders of Gonadal Development
A. Ç. Kuşkucu</td><td rowspan="3">Group A
Small Group Study
SRPC</td><td rowspan="3">Group B
ICP</td><td rowspan="3">Group C IL</td><td rowspan="3">Group D
ICP-CSL</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Insulin and Oral Antidiabetic Drugs I
E. Genç</td><td>Lecture
Hyperfunctioning Disorders of Anterior Pituitary Gland
F. Keleştimur</td><td>Lecture
The Gynecological History and Examination
G. Yıldırım</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Insulin and Oral Antidiabetic Drugs II
E. Genç</td><td>Lecture
Disorders of Posterior Pituitary Gland
F. Keleştimur</td><td>Lecture
Endometriosis & Adenomyosis
G. Yıldırım</td><td colspan="4">Independent Learning</td></tr>
<tr><td>12.50-14.00</td><td colspan="7">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Pathology of Pancreas I
A. Sav</td><td>Lecture
Hypopituatirism
F. Keleştimur</td><td>Lecture
Puerperal Infections
S. Özden</td><td>Lecture
Adrenocortical Hormones and Drugs I
E. Genç</td><td colspan="2" rowspan="2">ELECTIVE WEEK I</td><td colspan="2" rowspan="2">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Pathology of Pancreas II
A. Sav</td><td>Lecture
Diffuse Hormonal Systems and Endocrine Tumor Syndromes
H. Aydın</td><td>Lecture
Normal and Abnormal Labor
S. Özden</td><td>Lecture
Adrenocortical Hormones and Drugs II
E. Genç</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Pathology of Breast I
F. Özkan</td><td>Lecture
Thyroid Function Tests
H. Aydın</td><td>Independent Learning</td><td>Lecture
Pathology of Vulva & Vagina
F. Özkan</td><td colspan="2" rowspan="2">Independent Learning</td><td colspan="2" rowspan="2">ELECTIVE WEEK I</td></tr>
<tr><td>17.00-17.50</td><td>Lecture
Pathology of Breast II
F. Özkan</td><td>Lecture
Thyroid Disorders
H. Aydın</td><td>Independent Learning</td><td>Lecture
Pathology of Treponemal Infections
F. Özkan</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK III / 10-14 Feb 2020

<table>
<tr><th></th><th>Monday
10-Feb-2020</th><th>Tuesday
11-Feb-2020</th><th>Wednesday
12-Feb-2020</th><th>Thursday
13-Feb-2020</th><th>Friday
14-Feb-2020</th></tr>
<tr><td>09.00-09.50</td><td>Lecture
Antenatal Care
S. Özden</td><td>Lecture
The Menstrual Cycle and Disorders of the Menstrual Cycle
R. Attar</td><td>Lecture
Imaging of Urinary System
Ö. Sarıca</td><td>ICP-CSL
(Physical Examination of the Newborn and Child Patient)
Ç. Ayanoğlu/ M. Berber
ICP-CSL
(Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining)
R. Attar / G. Yıldırım</td><td>Lecture
Pathophysiology of Reproductive System Diseases I
M. Kaçar</td></tr>
<tr><td>10.00-10.50</td><td>Lecture
Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD)
S. Özden</td><td>Lecture
Normal and Abnormal Sexual Development & Puberty
R. Attar</td><td>Lecture
Menopause
Lecturer</td><td rowspan="2">Group A IL
Group B ICP-CSL
Group C ICP
Group D Small Group Study SRPC</td><td>Lecture
Pathophysiology of Reproductive System Diseases II
M. Kaçar</td></tr>
<tr><td>11.00-11.50</td><td>Lecture
Renovascular Pathology
A. Sav</td><td>Lecture
Fluid, Electrolyte I
G. Kantarcı</td><td>Lecture
Fertility Control
Lecturer</td><td>Lecture
Phytotherapy-VII
E. Yeşilada</td></tr>
<tr><td>12.00-12.50</td><td>Lecture
Renal Cystic Disease
A. Sav</td><td>Lecture
Fluid, Electrolyte II
G. Kantarcı</td><td>Lecture
Infertility
Lecturer</td><td colspan="2">Independent Learning</td><td>Lecture
Phytotherapy-VIII
E. Yeşilada</td></tr>
<tr><td>12.50-14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00-14.50</td><td colspan="2">Microbiology Laboratory
(Diagnostic Tests of Urinary Specimens)
Microbiology Instructors</td><td colspan="2">Microbiology Laboratory
(Diagnostic Tests of Urinary Specimens)
Microbiology Instructors</td><td>Lecture
Medical History for Breast Diseases in Primary Care & Clinical Breast Examination
A. Akalın</td><td>ICP-CSL
(Physical Examination of the Newborn and Child Patient)
Ç. Ayanoğlu / M. Berber
ICP-CSL
(Follow-up of Pregnancy & Stages of Normal Labour & Gynecological Examination, PAP Smear Obtaining)
R. Attar / G. Yıldırım</td><td rowspan="2">ELECTIVE WEEK II</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>15.00-15.50</td><td>Group A</td><td>Group B IL</td><td>Group C IL</td><td>Group D IL</td><td>Microbiology Laboratory
(Diagnostic tests of urinary specimens)
Microbiology nstructors</td><td>Group C</td><td>Group D IL</td><td>Group A & B IL</td><td>Independent Learning</td><td>Group A ICP-CSL</td><td>Group B IL</td><td>Group C Small Group Study SRPC</td><td>Group D ICP</td></tr>
<tr><td>16.00-16.50</td><td>Group A IL</td><td>Group B</td><td>Group C IL</td><td>Group D IL</td><td>Group C IL</td><td>Group D</td><td>Group A & B IL</td><td>Independent Learning</td><td colspan="4"></td><td>Independent Learning</td><td>ELECTIVE WEEK II</td></tr>
<tr><td>17.00-17.50</td><td colspan="2">Independent Learning</td><td colspan="3">Independent learning</td><td>Independent Learning</td><td colspan="4">Independent Learning</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK IV / 17-21 Feb 2020

<table>
<tr><th></th><th>Monday
17-Feb-2020</th><th>Tuesday
18-Feb-2020</th><th>Wednesday
19-Feb-2020</th><th>Thursday
20-Feb-2020</th><th>Friday
21-Feb-2020</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Normal Pubertal Development
B. Haliloğlu</td><td rowspan="4">OSCE-I EXAM</td><td rowspan="4">OSCE-I EXAM</td><td colspan="4">Independent Learning</td><td>Lecture
Pathology of Cervix Uteri I
F. Özkan</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pubertal Disorders
B. Haliloğlu</td><td colspan="4">ICP-CSL
(Clinical Breast Examination)
A. Akalın / Ö. Tanrıöver</td><td>Lecture
Pathology of Cervix Uteri II
F. Özkan</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Immunology of Reproduction
G. Yanıkkaya Demirel</td><td>Group A
ICP</td><td>Group B
Small Group
Study
SRPC</td><td>Group C IL</td><td>Group D IL</td><td>Lecture
Pathology of Pregnancy & Placenta
F. Özkan</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Immunology of Reproduction
G. Yanıkkaya Demirel</td><td colspan="4">Independent Learning</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Pathology of Bladder
F. Özkan</td><td rowspan="4">OSCE-I EXAM</td><td rowspan="4">OSCE-I EXAM</td><td colspan="2">Lecture
Congenital Infections and Sexually Transmitted Diseases, Genital Infections I
M. Sönmezoğlu</td><td rowspan="2">ELECTIVE
WEEK III</td><td rowspan="2">Independent
Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Pathology of Urinary System Tumors
F. Özkan</td><td colspan="2">Lecture
Congenital Infections and Sexually Transmitted Diseases, Genital Infections II
M. Sönmezoğlu</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Congenital Anomalies of Urinary System
F. Özkan</td><td colspan="2">Lecture
Congenital Infections and Sexually Transmitted Diseases, Genital Infections III
M. Sönmezoğlu</td><td rowspan="2">Independent
Learning</td><td rowspan="2">ELECTIVE
WEEK III</td></tr>
<tr><td>17.00-17.50</td><td>Lecture
Conditions Affecting Vulva & Vagina
O. Ünal</td><td colspan="2">Lecture
Congenital Anomalies of The Urinary System
Ş. Karaçay</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK V / 24-28 Feb 2020

	Monday 24-Feb-2020	Tuesday 25-Feb-2020	Wednesday 26-Feb-2020	Thursday 27-Feb-2020	Friday 28-Feb-2020
09.00- 09.50	**Lecture** Pathology of Glomerular Diseases I A. Sav	**Lecture** Pathology of Ovary I F. Özkan	**Lecture** Benign Diseases of the Uterus and the Cervix R. Attar	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Pathology of Glomerular Diseases II A. Sav	**Lecture** Pathology of Ovary II F. Özkan	**Lecture** Benign Diseases of the Ovary R. Attar	**ICP-CSL** (Clinical Breast Examination) A. Akalın/ Ö. Tanrıöver	
11.00- 11.50	**Lecture** Pathology of Glomerular Diseases III A. Sav	**Lecture** Pathology of Tubulointerstitial Disease I A. Sav	**Lecture** Nephritic Syndrome G. Kantarcı	**Group A IL** / **Group B IL** / **Group C Small Group Study** SRPC / **Group D**	
12.00- 12.50	**Lecture** Androgens & Anabolic Steroids E. Genç	**Lecture** Pathology of Tubulointerstitial Disease II A. Sav	**Lecture** Nephrotic Syndrome G. Kantarcı		
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Malign Diseases of the Uterus and the Cervix O. Ünal	**Lecture** Acute Kidney Injury-I G. Kantarcı	**Lecture** Agents Effecting Bone Mineral Homeostasis I E. Genç	**Lecture** The Kidney Systemic Disease and Inherited Disorders D. B. Ataş	**ELECTIVE WEEK IV** / **Independent Learning**
15.00- 15.50	**Lecture** Malign Diseases of the Ovary O. Ünal	**Lecture** Acute Kidney Injury-II G. Kantarcı	**Lecture** Agents Effecting Bone Mineral Homeostasis II E. Genç	**Lecture** The Kidney Systemic Disease and Inherited Disorders D. B. Ataş	
16.00- 16.50	**Lecture** Conditions Affecting Vulva & Vagina O. Ünal	**Independent Learning**	**Lecture** Pathology of Uterus I F. Özkan	**Lecture** Chromosomal Disorders I A. Ç. Kuşkucu	**Independent Learning** / **ELECTIVE WEEK IV**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Pathology of Uterus II F. Özkan	**Lecture** Chromosomal Disorders II (Sex Chromosomes and their Abnormalities) A. Ç. Kuşkucu	

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK VI / 2-6 Mar 2020

	Monday 2-Mar-2020	Tuesday 3-Mar-2020	Wednesday 4-Mar-2020	Thursday 5-Mar-2020	Friday 6-Mar-2020
09.00- 09.50	**Lecture** Benign Prostatic Hyperplasia-I F. Yencilek	**Lecture** Chronic Kidney Disease G. Kantarcı	**Lecture** Epidemiology, Prevention and Control of Type II Diabetes Mellitus R. E. Sezer	**Independent Learning**	**Microbiology Laboratory** (Diagnostic Tests of Urogenital Specimens) Microbiology Instructors; **Group D**; **Group C IL**; **Group A & B IL**
10.00- 10.50	**Lecture** Benign Prostatic Hyperplasia-II F. Yencilek	**Lecture** Chronic Kidney Disease G. Kantarcı	**Lecture** Acid/ Base Balance I D. B. Ataş	**ICP-CSL** (Clinical Breast Examination) A. Akalın/ Ö. Tanrıöver	**Group D IL**; **Group C**
11.00- 11.50	**Lecture** Urologic Emergencies F. Yencilek	**Lecture** Estrogens, Progestines and Inhibitors I E. N. Özdamar	**Lecture** Acid/ Base Balance II D. B. Ataş	**Group A** Small Group Study SRPC; **Group B ICP**; **Group C IL**; **Group D IL**	**Microbiology Laboratory** (Diagnostic Tests of Urogenital Specimens) Microbiology Instructors; **Group D & C IL**; **Group B**; **Group A IL**
12.00- 12.50	**Lecture** Approach to the Patient with Urinary Tract Symptoms F. Yencilek	**Lecture** Estrogens, Progestines and Inhibitors II E. N. Özdamar	**Lecture** Clinical Study of Renal Functions and Urinary Findings D. B. Ataş		**Group B IL**; **Group A**
12.50 -14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (Clinical Breast Examination) A. Akalın/ Ö. Tanrıöver	**ICP-CSL** (Clinical Breast Examination) A. Akalın/ Ö. Tanrıöver	**Lecture** Reproductive, Maternal and Child Health I H. A. Taşyıkan	**Lecture** Urologic Oncology I F. Yencilek	**ELECTIVE WEEK V**; **Independent Learning**
15.00- 15.50	**Group A** Small Group Study SRPC; **Group B ICP**; **Group C & D IL**	**Group A IL**; **Group B IL**; **Group C ICP**; **Group D** Small Group Study SRPC	**Lecture** Reproductive, Maternal and Child Health II H. A. Taşyıkan	**Lecture** Urologic Oncology II F. Yencilek	
16.00- 16.50			**Lecture** Reproductive, Maternal and Child Health II H. A. Taşyıkan	**Lecture** Upper and Lower Urinary Tract Infections I A.Ç. Büke	**Independent Learning**; **ELECTIVE WEEK V**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Upper and Lower Urinary Tract Infections II A.Ç. Büke	

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK VII / 9 - 13 Mar 2020

<table>
<tr><th></th><th colspan="3">Monday
9-Mar-2020</th><th>Tuesday
10-Mar-2020</th><th>Wednesday
11-Mar-2020</th><th>Thursday
12-Mar-2020</th><th>Friday
13-Mar-2020</th></tr>
<tr><td>09.00- 09.50</td><td colspan="3">Lecture
Pathophysiology of Urinary System Diseases I
M. Kaçar</td><td>Lecture
Hypothalamic and Pituitary Hormones I
E. N. Özdamar</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="3">Lecture
Pathophysiology of Urinary System Diseases II
M. Kaçar</td><td>Lecture
Hypothalamic and Pituitary Hormones II
E. N. Özdamar</td><td>Multidisciplinary Case Discussion Panel</td></tr>
<tr><td>11.00- 11.50</td><td colspan="3">Lecture
Pathology of Male Genital System I
F. Özkan</td><td>Lecture
Relation Between Several Variables
Ç. Altunok</td><td>Lecture
Tubulointerstitial Diseases
D. B. Ataş</td></tr>
<tr><td>12.00- 12.50</td><td colspan="3">Lecture
Pathology of Male Genital System II
F. Özkan</td><td>Lecture
Transplantation of Kidney
G. Tellioğlu</td><td>Lecture
Tubulointerstitial Diseases
D. B. Ataş</td></tr>
<tr><td>12.50- 14.00</td><td colspan="6">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="2">Pathology Laboratory
(Urinary System)
A.Sav / F. Özkan</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B</td><td>Lecture
Nephritic and Nephrotic Syndrome
D. Torlak</td><td>Lecture
Delivery of Family Planning Services I
A. Akalın</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
General Approach to the Pregnant Woman
Ö. Tanrıöver</td><td>Lecture
Delivery of Family Planning Services II
A. Akalın</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Pathology Laboratory
(Urinary System)
A.Sav / F. Özkan</td><td rowspan="2">Group A</td><td rowspan="2">Group B IL</td><td>Lecture
Embryology
O. Alagöz</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td>Independent Learning</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK VIII / 16 - 20 Mar 2020

<table>
<tr><th></th><th>Monday
16-Mar-2020</th><th>Tuesday
17-Mar-2020</th><th>Wednesday
18-Mar-2020</th><th>Thursday
19-Mar-2020</th><th colspan="2">Friday
20-Mar-2020</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td colspan="2">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="2" rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">LUNCH BREAK</td><td colspan="2">Program Evaluation Session
Committee IV
Coordination Committee Members</td></tr>
<tr><td>12.50- 14.00</td><td rowspan="5">Independent Learning</td><td rowspan="5">Independent Learning</td><td rowspan="5">Independent Learning</td><td rowspan="5">Independent Learning</td><td rowspan="2">ELECTIVE
WEEK VI</td><td rowspan="2">Independent
Learning</td></tr>
<tr><td>14.00- 14.50</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent
Learning</td><td rowspan="3">ELECTIVE
WEEK VI</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY

DISTRIBUTION of LECTURE HOURS

March 23, 2020 – May 8, 2020

COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	NEUROSURGERY	NRS	15	1x2=2 (2 Groups)			**17**
	NEUROLOGY	NR	13	1x4=4 (2 Groups)			**17**
	PHARMACOLOGY	PC	17				**17**
	PATHOLOGY	PT	11		1x2=2 (2 Groups)		**13**
	PSYCHIATRY	PCH	12				**12**
	PEDIATRICS	PED	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	FAMILY MEDICINE	FM	4				**4**
	BIOISTATISTICS	BS	3				**3**
	CHILD PSYCHIATRY	C-PCH	3				**3**
	MEDICAL GENETICS	MG	3				**3**
	OPHTALMOLOGY	OPT	3				**3**
	PATHOPHYSIOLOGY	PP	2				**2**
	IMMUNOLOGY	IMM	2				**2**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	2				**2**
	RADIOLOGY	RAD	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		100	6	2	2	**110**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				1x2=2 (4 Groups)	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**100**	**6**	**8**	**4**	**118**
	INDEPENDENT LEARNING						**103**

Coordination Committee

HEAD	N. Berfu Akbaş, MD, Assoc. Prof.
SECRETARY	Hakan Şilek, MD, Assist. Prof.
MEMBER	C. Kaan Yaltırık, MD, Assist. Prof.
MEMBER	Okan Taycan, MD, Assoc. Prof.
MEMBER	Erdem Söztutar, MD, Assist. Prof.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY
LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
NEUROLOGY	Berrin Aktekin, MD, Prof. Burcu Örmeci, MD, Assoc. Prof. Halide Rengin Bilgen, MD Hakan Şilek, MD
PSYCHIATRY	N. Berfu Akbaş, MD, Assoc. Prof. Okan Taycan, MD, Assoc. Prof.
CHILD PSYCHIATRY	Oğuzhan Zahmacıoğlu, MD, Assist. Prof
NEUROSURGERY	M. Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Volkan Harput, MD, Assist. Prof. C. Kaan Yaltırık, MD, Assist. Prof.
PATHOLOGY	Aydın Sav, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof.
PEDIATRICS	Mustafa Berber, MD, Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc. Prof. Özlem Tanrıöver, MD, Prof.
RADIOLOGY	O. Melih Topçuoğlu, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof.
OPHTALMOLOGY	Vildan Öztürk, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
EMERGENCY MEDICINE	Cem Şimşek, MD, Assist. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Halide Rengin Bilgen, MD Hakan Şilek, MD Naz Berfu Akbaş, MD, Assoc. Prof Oğuzhan Zahmacıoğlu, MD Assist. Prof Dilek Barutçu Ataş, MD, Assist. Prof. Kübra Yıldız, MD, Assist. Prof.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of nervous system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry ,
8. ***to convey*** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry***,***
9. ***to convey*** necessary knowledge on common problems in medical research,
10. ***to convey*** knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills *(suturing and tying-C7, neuropsychiatric evaluation-C7)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of nervous system,
2.0. ***define*** biochemical and psychodynamical basis of behavior,
3.0. ***grade*** physical, psychosocial and cognitive development of child,
4.0. ***explain*** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to to nervous system and psychiatry,
6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for

individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,

8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)

8.2. evaluation of emergency case (neurological emergencies-C7)

8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)

8.4. laboratory tests/examinations

8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)

8.6. point of care testing

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0. ***explain*** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallusinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,

10.0.***describe*** professional standards, organizational ethics, and ethics in psychiatry,

11.0. ***list*** common problems in medical research,

12.0. ***perform*** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
9.0	PC	E. Genç E. N. Özdamar	14	5	5	**24**
1.0, 4.0-8.0	NRS	M.G. Yaşargil U. Türe V. Harput K. Yaltırık	14	5	5	**24**
1.0, 4.0-8.0	NR	B. Aktekin B. Örmeci H. Şilek H. R. Bilgen	12	4	4	**20**
1.0, 2.0, 4.0-8.0, 10.0	PCH	B. Akbaş	10	4	4	**18**
1.0, 4.0, 7.0	PT	A. Sav	9	3	3	**15**
1.0, 3.0-8.0	PED	M. Berber	4	1	1	**6**
4.0, 7.0	IMM	G. Y. Demirel	2	1	1	**4**
5.0, 6.0	PH	R.E. Sezer	3	1	1	**5**
8.3	FM	G. İzbırak Ö. Tanrıöver	4	1	1	**6**
11.0	BS	Ç. Altunok	3	1	1	**5**
2.0	MG	A.Ç. Kuşkucu	3	1	1	**5**
2.0-8.0, 10.0	C-PCH	O. Zahmacıoğlu	3	1	1	**5**
1.0, 4.0-8.0	OPT	V. Öztürk	3	1	1	**5**
4.0, 7.0	PP	M. Kaçar	2	1	1	**4**
4.0-7.0, 8.4	IDCM	M. Sönmezoğlu	2	1	1	**4**
8.5	RAD	O.M. Topçuoğlu	1	0	0	**1**
8.2	EM	C. Şimşek	1	0	0	**1**
TOTAL			**90**	**31**	**31**	**152**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0., 4.0.-8.0.	NR	B. Örmeci	2	-	-	**2**
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B. Akbaş	2	-	-	**2**
1.0., 4.0.-8.0.	NRS	U. Türe	1	-	-	**1**
TOTAL			**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****31** out of 200 FE and ICE MCQs will be from Committee V (Each question is of worth 0.5 points).

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK I / 23-27 Mar 2020

	Monday 23-Mar-2020	Tuesday 24-Mar-2020	Wednesday 25-Mar-2020	Thursday 26-Mar-2020	Friday 27-Mar-2020	
09.00- 09.50	**Independent Learning**	**Lecture** Pathology of Myelin & Neuronal Storage Diseases I A. Sav	**Lecture** Peripheral Nerve Compression Sydromes Neurosurgery Lecturer	**Independent Learning**	**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders I E. Genç	
10.00- 10.50	**Lecture** Signs and Symptoms in Neurology B. Aktekin	**Lecture** Pathology of Myelin & Neuronal Storage Diseases II A. Sav	**Lecture** Epilepsy B. Aktekin		**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders II E. Genç	
11.00- 11.50	**Lecture** Cranial Nerves I B. Aktekin	**Lecture** Developmental Disorders of CNS A. Sav	**Lecture** Spinal Cord Compression and Spinal Tumors Neurosurgery Lecturer		**Lecture** Headache in Neurologic Patient H. Şilek	
12.00- 12.50	**Lecture** Cranial Nerves II B. Aktekin	**Lecture** Introduction to Central Nervous System Pharmacology E. Genç	**Lecture** Degenerative Diseases of the Spine and the Spinal Cord Neurosurgery Lecturer		**Lecture** Neurological Emergencies B. Örmeci	
12.50 – 14.00	**LUNCH BREAK**					
14.00- 14.50	**Lecture** Pathophysiology of Nervous System Diseases I M. Kaçar	**Lecture** Demyelinating Disorders I H. Şilek	**Lecture** Cerebral Lobes and their Disorders B. Örmeci	**Independent Learning**	**ELECTIVE WEEK VII Midterm Exam**	**Independent Learning**
15.00- 15.50	**Lecture** Pathophysiology of Nervous System Diseases II M. Kaçar	**Lecture** Demyelinating Disorders II H. Şilek	**Lecture** Dementia B. Örmeci			
16.00- 16.50	**Lecture** Neuroimmunological Disorders G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Extrapyramidal System Disorders B. Örmeci		**Independent Learning**	**ELECTIVE WEEK VII Midterm Exam**
17.00-17.50	**Lecture** Neuroimmunological Disorders G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Approach to Intoxicated Patient C. Şimşek			

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK II / 30 Mar - 3 Apr 2020

	Monday 30-Mar-2020	Tuesday 31-Mar-2020	Wednesday 1-Apr-2020				Thursday 2-Apr-2020				Friday 3-Apr-2020	
09.00- 09.50	**Lecture** Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient C. Kaan Yaltırık	**Lecture** Public Health and Aging I R. E. Sezer	**Neurology Clinical Training** H.Şilek				**Neurology Clinical Training** H. Şilek				**Lecture** Peripheral Nerve Disorders H. Şilek	
10.00- 10.50	**Lecture** Pediatric Neurosurgery C. Kaan Yaltırık	**Lecture** Public Health and Aging II R. E. Sezer	**Group A**	**Group B**	**Group C IL**	**Group D IL**	**Group A IL**	**Group B IL**	**Group C**	**Group D**	**Lecture** Cerebrovascular Disease H. Şilek	
11.00- 11.50	**Lecture** Hydrocephalus C. Kaan Yaltırık	**Lecture** Paralytic Strabismus and Nistagmus V. Öztürk									**Lecture** Cranial Trauma & Intracranial Hemorrhage I A. Sav	
12.00- 12.50	**Lecture** Neurosurgical Infections C. Kaan Yaltırık	**Lecture** Conventional Neuroradiological Examinations O. M. Topçuoğlu									**Lecture** Cranial Trauma & Intracranial Hemorrhage II A. Sav	
12.50 – 14.00	**LUNCH BREAK**											
14.00- 14.50	**Lecture** Neurodegenerative Disorders I A. Sav	**Lecture** Surgical Neuroanatomy U. Türe	**Independent Learning**				**Independent Learning**				**ELECTIVE WEEK VIII**	**Independent Learning**
15.00- 15.50	**Lecture** Neurodegenerative Disorders II A. Sav	**Lecture** Cerebrovascular Diseases in Neurosurgery I U. Türe										
16.00- 16.50	**Lecture** Infectious Disease of the Nervous System M. Berber	**Lecture** Cerebrovascular Diseases in Neurosurgery II U. Türe									**Independent Learning**	**ELECTIVE WEEK VIII**
17.00-17.50	**Lecture** Neurodegenerative Disorders M. Berber	**Independent Learning**										

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK III / 6-10 Apr 2020

	Monday 6-Apr-2020	Tuesday 7-Apr-2020	Wednesday 8-Apr-2020	Thursday 9-Apr-2020	Friday 10-Apr-2020
09.00- 09.50	**Lecture** Tumors of CNS I A. Sav	**Lecture** Antiepileptics E. Genç	**Neurosurgery Clinical Training** V. Harput	**Pathology Laboratory** **Lecture** Nervous System A.Sav	**Neurosurgery Clinical Training** C. Kaan Yaltırık
10.00- 10.50	**Lecture** Tumors of CNS II A. Sav	**Lecture** Functional Neurosurgery V. Harput	**Group A** | **Group B** | **Group C IL** | **Group D IL**	**Pathology Laboratory** **Lecture** Nervous System A.Sav	**Group A IL** | **Group B IL** | **Group C** | **Group D**
11.00- 11.50	**Lecture** Intracranial Tumors II M. Gazi Yaşargil	**Lecture** Spinal Trauma in Neurosurgery V. Harput	**Lecture** Genetic Etiology of Mental Retardation I A. Ç. Kuşkucu	**Pathology Laboratory** **Lecture** Nervous System A.Sav	**Lecture** Cerebral Malformations M. Berber
12.00- 12.50	**Lecture** Intracranial Tumors I M. Gazi Yaşargil	**Lecture** Cranial Trauma in Neurosurgery V. Harput	**Lecture** Genetic Etiology of Mental Retardation II A. Ç. Kuşkucu	**Pathology Laboratory** **Lecture** Nervous System A.Sav	**Lecture** Mental and Motor Development M. Berber
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Bipolar Disease & Lithium E. N. Özdamar	**Lecture** Culture, Health and Illness R. E. Sezer	**Lecture** Diseases of Optic Nerves and Visual Fields V. Öztürk	**Independent Learning**	**ELECTIVE WEEK IX** | **Independent Learning**
15.00- 15.50	**Lecture** Antipsychotic Drugs E. N. Özdamar	**Lecture** Behavioral Determinants of Health and Disease R. E. Sezer	**Lecture** Pupilla V. Öztürk		
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Independent Learning**		**Independent Learning** | **ELECTIVE WEEK IX**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**		

COMMITTEE V - NERVOUS SYSTEM and PYSCHIATRY
WEEK IV / 13-17 Apr 2020

	Monday 13-Apr-2020	Tuesday 14-Apr-2020	Wednesday 15-Apr-2020	Thursday 16-Apr-2020	Friday 17-Apr-2020
09.00- 09.50	**Lecture** Opioid Analgesics & Antagonists I E. Genç	**Lecture** Introduction to Psychiatry O. Taycan	**ICP-CSL** (General Physical Examination) D. B. Ataş/ F. Demircan	**ICP-CSL** (Neurological Examination & Psychiatric Examination) N. B. Akbaş/ O. Zahmacıoğlu/ H. Şilek	**Lecture** Analysis of Survival Studies I Ç. Altunok
10.00- 10.50	**Lecture** Opioid Analgesics & Antagonists II E. Genç	**Lecture** Psychiatric Interview, History O. Taycan	**Group A ICP** / **Group B IL** / **Group C IL** / **Group D IL**	**Group A Small Group Study** SRPC / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Analysis of Survival Studies II Ç. Altunok
11.00- 11.50	**Lecture** Psychiatric Epidemiology and Classification N.B. Akbaş	**Lecture** Acute and Chronic Meningitis, Encephalitis I M. Sönmezoğlu			**Lecture** Local Anesthetics E. Genç
12.00- 12.50	**Lecture** Antimigraine Drugs E. N. Özdamar	**Lecture** Acute and Chronic Meningitis, Encephalitis II M. Sönmezoğlu	**Independent Learning**	**Independent Learning**	**Lecture** General Anesthetics E. Genç
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Infectious Diseases of CNS I A. Sav	**Lecture** Design of Survival Studies Ç. Altunok	**ICP-CSL** (Neurological Examination & Psychiatric Examination) N. B. Akbaş/ O. Zahmacıoğlu/ H. Şilek	**ICP-CSL** (General Physical Examination) D. B. Ataş / F. Demircan	**ELECTIVE WEEK X** / **Independent Learning**
15.00- 15.50	**Lecture** Infectious Diseases of CNS II A. Sav	**Lecture** General Physical Examination D. B. Ataş	**Group A ICP** / **Group B Small Group Study** SRPC / **Group C IL** / **Group D IL**	**Group A IL** / **Group B ICP** / **Group C IL** / **Group D IL**	
16.00- 16.50	**Independent Learning**	**Independent Learning**			**Independent Learning** / **ELECTIVE WEEK X**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK V / 20-24 Apr 2020

	Monday 20-Apr-2020	Tuesday 21-Apr-2020	Wednesday 22-Apr-2020	Thursday 23-Apr-2020	Friday 24-Apr-2020
09.00- 09.50	**Lecture** Schizophrenia Spectrum and Other Psychotic Disorders I O. Taycan	**Lecture** Neuroscience I N.B. Akbaş	**ICP-CSL** (Neurological Examination & Psychiatric Examination) N.B. Akbaş / O. Zahmacıoğlu/ H. Şilek	**NATIONAL HOLIDAY**	**Independent Learning**
10.00- 10.50	**Lecture** Schizophrenia Spectrum and Other Psychotic Disorders II O. Taycan	**Lecture** Neuroscience II N.B. Akbaş	**Group A IL** / **Group B IL** / **Group D** Small Group Study SRPC / **Group C ICP**		
11.00- 11.50	**Lecture** Drug Dependence & Abuse E. Genç	**Lecture** Developmental Psychopathology: Risk and Protective Factors in Mental Development O. Taycan			
12.00- 12.50	**Lecture** The Alcohols E. Genç	**Lecture** Signs and Symptoms in Psychiatry O. Taycan			
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Genetic Aspects of Psychiatric Disorders A. Ç. Kuşkucu	**Independent Learning**	**ICP-CSL** (General Physical Examination) D. B. Ataş / F. Demircan	**NATIONAL HOLIDAY**	**ELECTIVE WEEK XI** / **Independent Learning**
15.00- 15.50	**Lecture** Antidepressant Drugs E. N. Özdamar		**Group A IL** / **Group B IL** / **Group D IL** / **Group C ICP**		
16.00- 16.50	**Lecture** Approach to Smoking Patient in Primary Care Ö. Tanrıöver				**Independent Learning** / **ELECTIVE WEEK XI**
17.00-17.50	**Independent Learning**		**Independent Learning**		

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK VI / 27 Apr – 1 May 2020

<table>
<tr><th></th><th>Monday
27-Apr-2020</th><th>Tuesday
28-Apr-2020</th><th>Wednesday
29-Apr-2020</th><th colspan="4">Thursday
30-Apr-2020</th><th>Friday
1-May-2020</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Depression in Primary Care
G. İzbırak</td><td rowspan="3">Independent Learning</td><td>Lecture
Introduction to Child and Adolescent Psychiatry
O. Zahmacıoğlu</td><td colspan="4">ICP-CSL
(Neurological Examination & Psychiatric Examination)
N.B. Akbaş / O. Zahmacıoğlu/ H. Şilek</td><td rowspan="4">LABOUR’S DAY</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Approach to the Patient with Dementia in Primary Care
G. İzbırak</td><td>Lecture
Common Childhood Psychiatric Problems
O. Zahmacıoğlu</td><td rowspan="3">Group A IL</td><td rowspan="3">Group B IL</td><td rowspan="3">Group D ICP</td><td rowspan="3">Group C Small Group Study
SRPC</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Sedative / Hypnotic Drugs I
E. Genç</td><td>Lecture
Mental Development in Childhood and Adolescence
O. Zahmacıoğlu</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Sedative / Hypnotic Drugs II
E. Genç</td><td>Lecture
CNS Stimulants and Hallusinogenic Drugs
E. Genç</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Mood Disorders I
B. Akbaş</td><td rowspan="4">Independent Learning</td><td>Multidisciplinary Case Discussion Panel</td><td colspan="4">ICP-CSL
(General Physical Examination)
D. B. Ataş / F. Demircan</td><td rowspan="4">LABOUR’S DAY</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Mood Disorders II
B. Akbaş</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="3">Group A IL</td><td rowspan="3">Group B IL</td><td rowspan="3">Group D ICP</td><td rowspan="3">Group C IL</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Anxiety Disorders: An Introduction
B. Akbaş</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td>Independent Learning</td><td colspan="4">Independent Learning</td></tr>
</table>

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK VII / 4-8 May 2020

<table>
<tr><th></th><th>Monday
4-May-2020</th><th>Tuesday
5-May-2020</th><th>Wednesday
6-May-2020</th><th>Thursday
7-May-2020</th><th colspan="2">Friday
8-May-2020</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td colspan="2">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="2" rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">LUNCH BREAK</td><td colspan="2">Program Evaluation Session
Committee V
Coordination Committee
Members</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="2">ELECTIVE
WEEK XII</td><td rowspan="2">Independent
Learning</td></tr>
<tr><td>15.00- 15.50</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Independent
Learning</td><td rowspan="2">ELECTIVE
WEEK XII</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

DISTRIBUTION of LECTURE HOURS

May 11, 2020 – June 12, 2020

COMMITTEE DURATION: 5 WEEKS

MED 302	INTRODUCTION to CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	ORTHOPAEDICS & TRAUMATOLOGY	ORT	19				**19**
	PATHOLOGY	PT	13		1x2=2 (4 Groups)		**15**
	RHEUMATOLOGY	RHE	9				**9**
	PHARMACOLOGY	PC	5				**5**
	PHYSICAL MEDICINE AND REHABILITATION	PTR	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	BIOSTATISTICS	BS	3				**3**
	PATHOPHYSIOLOGY	PP	2				**2**
	IMMUNOLOGY	IMM	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	2				**2**
	RADIOLOGY	RAD	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
	TOTAL		66		2	2	**70**
	OTHER COURSES						
	SCIENTIFIC RESEARCH and PROJECT COURSE-III	SRPC				1x2=2 (4 Groups)	**2**
MED 303	INTRODUCTION to CLINICAL PRACTICE III	ICP III			1x3=3 (4 Groups)		**3**
TOTAL			**66**		**5**	**4**	**75**
	INDEPENDENT LEARNING						**81**

Coordination Committee

HEAD	Müge Bıçakçıgil Kalaycı, MD, Assoc. Prof
SECRETARY	Onur Kocadal, MD, Assist. Prof.
MEMBER	Gökhan Meriç, MD, Assoc. Prof.
MEMBER	Özgür Ortancıl, MD, Prof.
MEMBER	Pınar Tura, MD, Assist. Prof.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

LECTURERS

MED 302 INTRODUCTION to CLINICAL SCIENCES	
DISCIPLINE	**FACULTY**
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD, Prof. Turhan Özler, MD, Assoc. Prof. Gökhan Meriç, MD, Assoc. Prof. Hakan Turan Çift, MD, Assoc. Prof. Onur Kocadal, MD, Assist. Prof. Burak Çağrı Aksu, MD, Assist. Prof.
PHYSICAL MEDICINE AND REHABILITATION	Özgür Ortancıl, MD, Prof.
RHEUMATOLOGY	Müge Bıçakçıgil Kalaycı, MD, Assoc. Prof
PATHOLOGY	Aydın Sav, MD, Prof. Ferda Özkan, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Emine Nur Özdamar, MD, Assist. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Assist. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc. Prof Pınar Tura, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Assist. Prof.
OTHER COURSES	
DISCIPLINE	**LECTURERS**
SCIENTIFIC RESEARCH and PROJECT COURSE-III	Bayram Yılmaz, PhD, Prof. Hale Arık Taşyıkan, MD, Assist Prof.

MED 303 INTRODUCTION to CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Hakan Turan Çift, MD, Assoc Prof. Gökhan Meriç, MD, Assoc Prof. Onur Kocadal, MD.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. ***to convey*** necessary knowledge on ethics in biomedical research,
9. ***to convey*** necessary knowledge on clinical research methods and searching medical literature,
10. ***to convey*** necessary knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of musculoskeletal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, onocological conditions of bone, rheumotological disorders, disaeses/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,

5.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (musculoskeletal-C8)
6.2. evaluation of emergency case (trauma-C8)
6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
6.4. laboratory tests/examinations (monitarization of drug therapy-C8)
6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient
7.0. ***explain*** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants, disease modifying antirheumatic drugs) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8.0. ***explain*** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,
9.0.***explain*** use of biostatistics in clinical research and for evidence search in medical literature,
10.0. ***perform*** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MED 302 INTRODUCTION to CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE VI - MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**DISCIPLINE**	**LECTURER/ INSTRUCTOR**	**NUMBER of QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0-6.10	ORT	F. Altıntaş B. Ç. Aksu T. Özler G. Meriç O. Kocadal H. T. Çift	24	7	7	**38**
1.0, 2.0, 5.0	PT	F. Özkan A. Sav	18	4	4	**26**
1.0.-6.0	RHE	M. Bıçakçıgil Kalaycı	13	3	3	**19**
7.0.	PC	E. Genç E. N. Özdamar	7	2	2	**11**
3.0, 4.0	PH	R.E. Sezer H.A.Taşyıkan	5	1	1	**7**
1.0-6.0	PTR	Ö. Ortancıl	5	1	1	**7**
1.0, 2.0, 5.0	IMM	G. Y. Demirel	3	1	1	**5**
9.0	BS	Ç. Altunok	4	1	1	**6**
1.0, 2.0, 5.0	PP	M. Kaçar	3	1	1	**5**
2.0	MG	A.Ç. Kuşkucu	3	0	0	**3**
6.2	EM	S. Sarıkaya P. Tura	4	1	1	**6**
6.5	RAD	N. Taşdelen	1	0	0	**1**
		TOTAL	**90**	**22**	**22**	**134**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER / INSTRUCTOR**	**NUMBER of QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0.-6.0	RHE	M. Bıçakçıgil Kalaycı	2	-	-	2
1.0-6.10	ORT	O. Kocadal	2	-	-	2
1.0-6.0	PTR	Ö. Ortancıl	1			1
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

Abbreviations

MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****21** out of 200 FE and ICE MCQs will be from Committee VI (Each question is of worth **0.5** pts).

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK I / 11-15 May 2020

	Monday 11-May-2020	Tuesday 12-May-2020	Wednesday 13-May-2020	Thursday 14-May-2020	Friday 15-May-2020
09.00- 09.50	**Lecture** Introduction to Musculoskeletal System F. Altıntaş	**Lecture** Degenerative Joint Disease F. Özkan	**Lecture** Osteoporosis and Osteoarthritis Treatment, Rehabilitation Ö. Ortancıl	**ICP-CSL** (Physical Examination of the Musculoskeletal System) G. Meriç / O. Kocadal	**Lecture** Public Health and Physical Activity I R. E. Sezer
10.00- 10.50	**Lecture** Degenerative Osteoarthrosis F. Altıntaş	**Lecture** Tumors of Soft Tissues I F. Özkan	**Lecture** Soft Tissue Pain Ö. Ortancıl	**Group A ICP** / **Group B Small Group Study** SRPC / **Group C IL** / **Group D IL**	**Lecture** Public Health and Physical Activity II R. E. Sezer
11.00- 11.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders I M. Kaçar	**Lecture** Tumors of Soft Tissues II F. Özkan	**Lecture** Bone and Joint Infections Pathology Lecturer		**Lecture** Vasculitis I F. Özkan
12.00- 12.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders II M. Kaçar	**Lecture** Frostbite / Burns P. Tura	**Lecture** Myopathies Pathology Lecturer	**Independent learning**	**Lecture** Vasculitis II F. Özkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Congenital & Metabolic Diseases of Bone I Pathology Lecturer	**Lecture** Spondylarthropaties M. Bıçakçıgil Kalaycı	**Lecture** Foot Deformities B. Ç. Aksu	**Independent Learning**	**ELECTIVE WEEK XIII** / **Independent Learning**
15.00- 15.50	**Lecture** Congenital & Metabolic Diseases of Bone II Pathology Lecturer	**Lecture** Inflammatory Polyarthritis & Rheumatoid Arthritis M. Bıçakçıgil Kalaycı	**Lecture** Principles of Fracture Healing B. Ç. Aksu		
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Initial Approach to Trauma Patient S. Sarıkaya		**Independent Learning** / **ELECTIVE WEEK XIII**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**		

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK II / 18-22 May 2020

	Monday 18-May-2020	Tuesday 19-May-2020	Wednesday 20-May-2020	Thursday 21-May-2020	Friday 22-May-2020
09.00- 09.50	**Lecture** Imaging of Musculoskeletal System N. Taşdelen	NATIONAL HOLIDAY	**Lecture** Osteomyelitis O. Kocadal	**ICP-CSL** (Physical Examination of the Musculoskeletal System) G. Meriç / O. Kocadal	**Lecture** Lower Extremity Trauma G. Meriç
10.00- 10.50	**Lecture** Miscellanous Rheumatological Disorders I M. Bıçakçıgil Kalaycı		**Lecture** Septic Artritis O. Kocadal	**Group A** Small Group Study SRPC / **Group B** ICP / **Group C** IL / **Group D** IL	**Lecture** Traumatic Dislocations G. Meriç
11.00- 11.50	**Lecture** Miscellanous Rheumatological Disorders II M. Bıçakçıgil Kalaycı		**Lecture** Development Dysplasia of the Hip O. Kocadal		**Lecture** Spinal Trauma G. Meriç
12.00- 12.50	**Lecture** Miscellanous Rheumatological Disorders III M. Bıçakçıgil Kalaycı		**Lecture** Upper Extremity Trauma O. Kocadal	**Independent Learning**	**Lecture** Skeletal Dysplasias A. Ç. Kuşkucu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Neck, Shoulder and Wrist Pain Ö. Ortancıl	NATIONAL HOLIDAY	**ICP-CSL** (Physical Examination of the Musculoskeletal System) H. T. Çift / O. Kocadal / G. Meriç	**ICP-CSL** (Physical Examination of the Musculoskeletal System) H. T. Çift / O. Kocadal	**ELECTIVE WEEK XIV** / **Independent Learning**
15.00- 15.50	**Lecture** Low Back, Hip and Ankle Pain Ö. Ortancıl		**Group A** IL / **Group B** IL / **Group C** Small Group Study SRPC / **Group D** ICP	**Group A** IL / **Group B** IL / **Group C** ICP / **Group D** Small Group Study SRPC	
16.00- 16.50	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries I H.A. Taşyıkan				**Independent Learning** / **ELECTIVE WEEK XIV**
17.00-17.50	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries II H.A. Taşyıkan		**Independent Learning**	**Independent Learning**	

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK III / 25-29 May 2020

	Monday 25-May-2020	Tuesday 26-May-2020	Wednesday 27-May-2020	Thursday 28-May-2020	Friday 29-May-2020
09.00- 09.50	**RELIGIOUS HOLIDAY**	**RELIGIOUS HOLIDAY**	**Lecture** Connective Tissue Disorders I M. Bıçakçıgil Kalaycı	**Lecture** Spinal Deformities H. T. Çift	**Lecture** Management of the Trauma Patient T. Özler
10.00- 10.50			**Lecture** Connective Tissue Disorders II M. Bıçakçıgil Kalaycı	**Lecture** Osteoporosis H. T. Çift	**Lecture** Complications of Fractures G. Meriç
11.00- 11.50			**Lecture** Nonsteroidal Antiinflammatory Drugs I E. Genç	**Lecture** Benign Tumors of Bone H. T. Çift	**Lecture** Some Common Problems in Medical Research Ç. Altunok
12.00- 12.50			**Lecture** Nonsteroidal Antiinflammatory Drugs II E. Genç	**Lecture** Malignant Tumors of Bone H. T. Çift	**Lecture** Power Analysis and Sample Size Calculation I Ç. Altunok
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**RELIGIOUS HOLIDAY**	**RELIGIOUS HOLIDAY**	**Independent Learning**	**Independent Learning**	**ELECTIVE COURSE MAKE-UP EXAM**
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK IV / 1-5 June 2020

<table>
<tr><th></th><th>Monday
1-Jun-2020</th><th>Tuesday
2-Jun-2020</th><th>Wednesday
3-Jun-2020</th><th>Thursday
4-Jun-2020</th><th>Friday
5-Jun-2020</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Disease Modifying Antirheumatic Drugs
Pharmacology Lecturer</td><td colspan="2">Lecture
Autopsy I
A. Sav</td><td>Lecture
Vasculitis I
M. Bıçakçıgil Kalaycı</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pharmacology Case Studies
Pharmacology Lecturer</td><td colspan="2">Lecture
Autopsy II
A. Sav</td><td>Lecture
Vasculitis II
M. Bıçakçıgil Kalaycı</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Immune Mechanisms of Musculoskeletal Disorders
G. Yanıkkaya Demirel</td><td colspan="2">Lecture
Power Analysis and Sample Size Calculation II
Ç. Altunok</td><td>Lecture
Management of Soft Tissue Disorders
T. Özler</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Immune Mechanisms of Musculoskeletal Disorders
G. Yanıkkaya Demirel</td><td colspan="2">Lecture
Muscular Dystrophies
A. Ç.Kuşkucu</td><td>Lecture
Fractures of Children
T. Özler</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Skeletal Muscle Relaxants
E. Genç</td><td colspan="2">Lecture
Bone Tumors I
Pathology Lecturer</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="4">Independent Learning</td><td rowspan="4">ELECTIVE COURSE FINAL EXAM</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td><td colspan="2">Lecture
Bone Tumors II
Pathology Lecturer</td><td>Multidisciplinary Case Discussion Panel</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Pathology Laboratory (Musculoskeletal System)
A.Sav / F. Özkan</td><td>Group A
IL</td><td>Group B
IL</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td>Group A
IL</td><td>Group B</td><td>Independent Learning</td></tr>
</table>

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK V / 8-12 June 2020

	Monday 8-Jun-2020	Tuesday 9-Jun-2020	Wednesday 10-Jun-2020	Thursday 11-Jun-2020	Friday 12-Jun-2020
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					
11.00- 11.50					COMMITTEE EXAM
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				Program Evaluation Session Committee VI Coordination Committee Members
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life.
The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.
The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

The topics that will be addressed by the consultants are as follows:

a. Inform students about the university, faculty and surrounding facilities
b. Inform students about the courses and help them select courses
c. Inform students about the education and assessment regulations
d. Follow students attendance to lectures and success
e. In case of failure, investigate the causes and cooperate with the students to overcome them
f. Help students in career planning
g. Contribute to students adapting the habit of lifelong learning
h. Guide students to counseling services of the university
i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

The expectations from the student are as follows:

a) Contribute to improvement of satisfaction level in the problem areas
b) Report the social and economic conditions that require consultant's help
c) Specify expectations from the education and the department from which this training is taken
d) Give feedback on the counseling services regarding their satisfaction level

Student counsellors will be appointed after finalization of the class list and will be announced to the students.
After the announcement of the counsellors on the information board, each student is expected to contact his/her counsellor until the end of the current committee.

LIST OF STUDENT COUNSELING - PHASE III

	NAME	SURNAME	COUNSELOR
1	SEYYED SHAHAB	ABOUTALEBI	PROF. DR. TURGAY İSBİR
2	MEHMET DORUK	ACET	PROF. DR. TURGAY İSBİR
3	KARDELEN	AKGÜN	PROF. DR. TURGAY İSBİR
4	SHIRIN	ALANSARI	PROF. DR. TURGAY İSBİR
5	BERİL	ARISOY	DR. ÖĞR. ÜYESİ ÇİĞDEM ALTUNOK
6	DORUK	ARSLAN	PROF. DR. ECE GENÇ
7	ELA	ASLANSOY	PROF. DR. ECE GENÇ
8	İREM	AYDIN	PROF. DR. ECE GENÇ
9	MOHAMAD IBRAHIM	BADENJKI	PROF. TURGAY İSBİR
10	NİL BAŞAK	BAŞAK	PROF. DR. ECE GENÇ
11	DURU	BAYKAL	PROF. DR. ECE GENÇ
12	ANİSA	BEYAN	PROF. DR. ECE GENÇ
13	BATUHAN	BİLGİN	PROF. DR. EROL SEZER
14	CANDAN	BİRDAL	PROF. DR. EROL SEZER
15	ÖZLEM	BURÇ	PROF. DR. EROL SEZER
16	ÇAĞLA ZEHRA	BÜYÜKKOÇ	PROF. DR. EROL SEZER
17	CEREN	CANŞE	PROF. DR. EROL SEZER
18	ENİS	CEVRİOĞLU	PROF. DR. EROL SEZER
19	SEDA	CEYLAN	PROF. DR. EROL SEZER
20	ZEYNEP SERRA	COŞKUN	PROF. DR. EROL SEZER
21	BORA	ÇAĞAN	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
22	AYHAN	ÇELİKAYAK	PROF. DR. EROL SEZER
23	ALİ FETİH	ÇETİN	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
24	ZEYNEP	DAL	PROF. DR. İNCİ ÖZDEN
25	ZEKERİYA ALP	DEMİRSOY	PROF. DR. İNCİ ÖZDEN
26	EFE	DEMOKAN	PROF. DR. İNCİ ÖZDEN
27	GÖNÜL BERFİN	DENİZ	PROF. DR. İNCİ ÖZDEN
28	KAĞAN	DİLEK	PROF. DR. İNCİ ÖZDEN
29	SEÇİL NUR	DİNÇER	PROF. DR. İNCİ ÖZDEN
30	MERT	EGE	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
31	GÜLİNA	EKMEN	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
32	EBRAR CEMRE	ELMALI	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
33	CEYDA	ERALP	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
34	HAZAL	ERDEM	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
35	ÇAĞLA	EREK	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
36	ORHAN SELİM	ERGİN	PROF. DR. GÜLDEREN YANIKKAYA DEMİREL
37	GÖZDE	ERĞUT	DOÇ. DR. ÇAĞATAY ACUNER
38	BAŞAK SILA	ERYİĞİT	DOÇ. DR. ÇAĞATAY ACUNER
39	DEREN	ESENCAN	DOÇ. DR. ÇAĞATAY ACUNER
40	DAVID SINAN	ESENSOY	DOÇ. DR. ÇAĞATAY ACUNER
41	ECE	EZELSOY	DOÇ. DR. ÇAĞATAY ACUNER
42	BEGÜM	EZELSOY	DOÇ. DR. ÇAĞATAY ACUNER
43	ALİ	FARUK	DOÇ. DR. ÇAĞATAY ACUNER

44	EGE	FIRILOĞLU	DOÇ. DR. ÇAĞATAY ACUNER
45	MELTEM	GEZERTAŞAR	DOÇ. DR. ÇAĞATAY ACUNER
46	BURAK	GÖNÜLLÜ	DOÇ. DR. ÇAĞATAY ACUNER
47	IŞIL	GÜLSEREN	DOÇ. DR. SONER DOĞAN
48	SEZİ CEREN	GÜNAY	DOÇ. DR. SONER DOĞAN
49	İREM	GÜNER	DOÇ. DR. SONER DOĞAN
50	MERT	GÜNEŞ	DOÇ. DR. SONER DOĞAN
51	ÖYKÜ	GÜVEN	DOÇ. DR. SONER DOĞAN
52	AHMET BERK	GÜZELCE	DOÇ. DR. SONER DOĞAN
53	BERNA	HADDAD	DOÇ. DR. SONER DOĞAN
54	EDA	HASBAY	PROF. DR. ÖZLEM TANRIÖVER
55	ELİZ	HASBAY	PROF. DR. ÖZLEM TANRIÖVER
56	CEYHUN	HAZIROĞLU	PROF. DR. ÖZLEM TANRIÖVER
57	ÖZGE	HIDIROĞLU	PROF. DR. İNCİ ÖZDEN
58	SELİN	İSMAİLOĞLU	PROF. DR. ÖZLEM TANRIÖVER
59	UMUT	KARAÇAM	PROF. DR. ÖZLEM TANRIÖVER
60	DİLAN	KARAÇAM	PROF. DR. ÖZLEM TANRIÖVER
61	TUNAHAN	KARAÇOBAN	DR. ÖĞR. ÜYESİ ÇİĞDEM ALTUNOK
62	EKİN	KARAGÖLENT	DOÇ. DR. MEHTAP KAÇAR
63	CEREN	KARCEBAŞ	DOÇ. DR. ÖZLEM TANRIÖVER
64	MAİDE	KARGILI	DOÇ. DR. MEHTAP KAÇAR
65	BEGÜM	KAŞ	DR. ÖĞR. ÜYESİ ARZU AKALIN
66	ALP	KAVAKLIOĞLU	DOÇ. DR. MEHTAP KAÇAR
67	CEREN NAZ	KAVLAK	DOÇ. DR. MEHTAP KAÇAR
68	HELİN	KAYA	DOÇ. DR. MEHTAP KAÇAR
69	RANA BURKE	KAYA	DOÇ. DR. MEHTAP KAÇAR
70	SERAY	KAYMAKCI	DOÇ. DR. MEHTAP KAÇAR
71	BENGİSU	KESKİN	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
72	AMAL	KERDJADJ	DOÇ. DR. MEHTAP KAÇAR
73	İREM	KIYIPINAR	DR. ÖĞR. ÜYESİ ALEV CUMBUL
74	SARP	KOCA	DOÇ. DR. DENİZ KIRAÇ
75	NAZLI	KOCAOĞLU	DOÇ. DR. DENİZ KIRAÇ
76	EYLÜL	KOÇ	DOÇ. DR. DENİZ KIRAÇ
77	METE	KORKMAZ	DOÇ. DR. DENİZ KIRAÇ
78	ZEYNEP	KÖFTECİ	DOÇ. DR. DENİZ KIRAÇ
79	DENİZ	KÖSE	DOÇ. DR. DENİZ KIRAÇ
80	DUYGU	KURT	DR. ÖĞR. ÜYESİ ALEV CUMBUL
81	BÜŞRA	KÜÇÜKYILDIZ	DR. ÖĞR. ÜYESİ ALEV CUMBUL
82	FADİME	MAN	DR. ÖĞR. ÜYESİ ALEV CUMBUL
83	KAAN	MANDIRACI	DR. ÖĞR. ÜYESİ ALEV CUMBUL
84	SUDE	MENEKŞE	DR. ÖĞR. ÜYESİ ALEV CUMBUL
85	ECEM	MEŞECİ	DR. ÖĞR. ÜYESİ SERDAR ÖZDEMİR
86	FARHİA	MOHAMED MURSAL	DR. ÖĞR. ÜYESİ SERDAR ÖZDEMİR
87	NEDİ	MOTRO	DR. ÖĞR. ÜYESİ SERDAR ÖZDEMİR
88	ECE	MUTLUAY	DR. ÖĞR. ÜYESİ SERDAR ÖZDEMİR

89	ASENA	NUHOĞLU	DR. ÖĞR. ÜYESİ SERDAR ÖZDEMİR
90	ZEYNEP	ORDUSEVEN	DR. ÖĞR. ÜYESİ SERDAR ÖZDEMİR
91	ONUR	ORHAN	DR. ÖĞR. ÜYESİ BİLGE GÜVENÇ TUNA
92	RAWAN	OSMAN	DR. ÖĞR. ÜYESİ BİLGE GÜVENÇ TUNA
93	CANSU	ÖLMEZ	DR. ÖĞR. ÜYESİ BİLGE GÜVENÇ TUNA
94	FULYA	ÖNÜGÖR	DR. ÖĞR. ÜYESİ BİLGE GÜVENÇ TUNA
95	TUTKU NAZ	ÖZDEMİR	DR. ÖĞR. ÜYESİ BİLGE GÜVENÇ TUNA
96	ŞEVVAL ÖZLEM	ÖZEL	DR. ÖĞR. ÜYESİ BİLGE GÜVENÇ TUNA
97	ECE	ÖZEL	DR. ÖĞR. ÜYESİ ARZU AKALIN
98	SELAHATTİN ALP	ÖZKÖK	DR. ÖĞR. ÜYESİ ARZU AKALIN
99	BERRA	ÖZTÜRK	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
100	DEMİR CAN	PATA	DR. ÖĞR. ÜYESİ ARZU AKALIN
101	SAİT EGEMEN	PEKŞEN	DR. ÖĞR. ÜYESİ ARZU AKALIN
102	GÖKSU	SAYGILI	DR. ÖĞR. ÜYESİ ARZU AKALIN
103	ALP	SEÇER	DR. ÖĞR. ÜYESİ ARZU AKALIN
104	ÇAĞLA	SELÇUK	DR. ÖĞR. ÜYESİ ARZU AKALIN
105	MEHMET ALİ	SERDAROĞLU	DOÇ. DR. BURCU GEMİCİ
106	BUKET	SERİM	DOÇ. DR. BURCU GEMİCİ
107	ÖMER	SÖNMEZ	DR. ÖĞR. ÜYESİ ARZU AKALIN
108	ENES TANER	SÖNMEZIŞIK	DOÇ. DR. BURCU GEMİCİ
109	MELİS ECE	ŞAHİNER	DOÇ. DR. BURCU GEMİCİ
110	HAYDAR	ŞENDUR	DR. ÖĞR. ÜYESİ ÇİĞDEM ALTUNOK
111	PELİN	ŞENGÜDER	DR. ÖĞR. ÜYESİ ÇİĞDEM ALTUNOK
112	İPEK	TANAÇAR	DR. ÖĞR. ÜYESİ ÇİĞDEM ALTUNOK
113	MUSTAFA ALİHAN	TÜRK	DR. ÖĞR. ÜYESİ ÇİĞDEM ALTUNOK
114	CEMAL	ULUSOY	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
115	SELİN	UYAR	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
116	MERVE	UYSAL	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
117	SEDAT	ÜÇAR	DR. ÖĞR. ÜYESİ HALE ARIK TAŞYIKAN
118	METEHAN	YELMENOĞLU	DOÇ. DR. AYLİN YABA UÇAR
119	SU	YILDIRIM	DOÇ. DR. AYLİN YABA UÇAR
120	ONUR	YILMAZ	DOÇ. DR. AYLİN YABA UÇAR
121	NUR RİMA	YOLA	DOÇ. DR. BURCU GEMİCİ
122	MEHMET ALİ	YÜCEL	DOÇ. DR. AYLİN YABA UÇAR
123	GÖKTUĞ	YÜKSEL	DOÇ. DR. AYLİN YABA UÇAR

CONTACT

Faculty Secretary :
Tel: +90 216 578 00 00 (3005)

Dean Secretary:
Tel: +90 216 578 05 05 – 06
Fax: +90 216 578 05 75

Student Affairs :
Tel: +90 216 578 06 86

Documents Affairs:
Tel: +90 216 578 05 93

Phase 3 Coordinator/ Co-coordinators:

Hale Arık Taşyıkan, MD, Assist. Prof. (Coordinator), 0216 578 00 00 (6300) / hale.arik@yeditepe.edu.tr

Hasan Aydın, MD, Prof. (Co-coordinator), 0216 578 00 00 (4095) / haydin@yeditepe.edu.tr

Erdem Söztutar, Assist. Prof (Co-coordinator), 0216 578 00 / erdem.soztutar@yeditepe.edu.tr

Emine Nur Özdamar, Assist. Prof (Co-coordinator), 0216 578 00 / nur.ozdamar@yeditepe.edu.tr

Özlem Tanrıöver, MD, Prof. (ICP Coordinator), 216 578 00 00 (3742) / otanriover@yeditepe.edu.tr

A. Arzu Akalın, MD, Assist. Prof. (ICP Co-coordinator & Elective Courses Coordinator), 216 578 00 00 (1525) / arzu.akalin@yeditepe.edu.tr

Seda Güleç, PhD. Assoc. Prof. (Elective Courses Co-coordinator)

Address:

Yeditepe University Faculty of Medicine
İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

Web : www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
e-mail: tipfakdek@yeditepe.edu.tr

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE

İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
tipfakdek@yeditepe.edu.tr